{"id":12718,"date":"2026-02-17T18:46:40","date_gmt":"2026-02-17T18:46:40","guid":{"rendered":"https:\/\/csiag.eu\/?p=12718"},"modified":"2026-02-17T20:56:03","modified_gmt":"2026-02-17T20:56:03","slug":"mogad-mog-anti%cc%87kor-i%cc%87li%cc%87ski%cc%87li%cc%87-hastalik","status":"publish","type":"post","link":"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/","title":{"rendered":"MOGAD - MOG antikoru ile ili\u015fkili hastal\u0131k"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_87_1 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">\u0130\u00e7indekiler tablosu<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_ist_MOGAD\" >MOGAD nedir?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_geht_bei_MOGAD_schief\" >MOGAD'da yanl\u0131\u015f giden ne?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wo_im_Korper_passiert_das\" >Bu v\u00fccudun neresinde olur?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_verlauft_die_Erkrankung\" >Hastal\u0131k nas\u0131l ilerliyor?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_haufig_ist_MOGAD\" >MOGAD ne kadar yayg\u0131nd\u0131r?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_lost_MOGAD_aus\" >MOGAD'\u0131 ne tetikler?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_wird_MOGAD_behandelt\" >MOGAD nas\u0131l tedavi edilir?<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wissenschaftliche_Einleitung_und_Definition\" >Bilimsel giri\u015f ve tan\u0131m<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Abgrenzung_von_MOGAD_NMOSD_und_MS\" >MOGAD, NMOSD ve MS aras\u0131ndaki farkl\u0131la\u015fma<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\" >MOG proteini - yap\u0131s\u0131 ve fizyolojik i\u015flevi<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Strukturdomanen\" >Yap\u0131sal alanlar<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Physiologische_Funktionen\" >Fizyolojik i\u015flevler<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Pathogenese_und_Immunpathologie\" >Patogenez ve imm\u00fcnopatoloji<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Trigger_und_initiale_Aktivierung\" >Tetikleme ve ilk aktivasyon<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-vermittelte_Pathogenese\" >T-h\u00fccresi arac\u0131l\u0131 patogenez<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_%E2%80%93_Periphere_Aktivierung\" >A\u015fama 1 - Periferik aktivasyon<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_%E2%80%93_BHS-Penetration\" >A\u015fama 2 - BHS penetrasyonu<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\" >A\u015fama 3 - Perivask\u00fcler reaktivasyon<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#B-Zell-_und_Antikorper-vermittelte_Pathogenese\" >B-h\u00fccresi ve antikor arac\u0131l\u0131 patogenez<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Molekulare_Signalwege_und_Effektormechanismen\" >Molek\u00fcler sinyal yollar\u0131 ve efekt\u00f6r mekanizmalar\u0131<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\" >Sinyalizasyon yolu 1 - klasik kompleman yolu (CDC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\" >Sinyalizasyon yolu 2 - Fc\u03b3 resept\u00f6r yolu (FcR arac\u0131l\u0131)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\" >Sinyalizasyon yolu 3 - IL-6\/JAK-STAT3 yolu<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\" >Sinyalizasyon yolu 4 - MAPK ve AKT sinyalizasyon yollar\u0131 (B h\u00fccreleri)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\" >Sinyalizasyon yolu 5 - MSS'de Th17 sitokin a\u011f\u0131<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalwege_%E2%80%93_Ubersicht\" >Sinyalizasyon yollar\u0131 - genel bak\u0131\u015f<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Relevante_Rezeptoren_und_Zielmolekule\" >\u0130lgili resept\u00f6rler ve hedef molek\u00fcller<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\" >Hedef yap\u0131 olarak MOG'un kendisi (klasik bir resept\u00f6r de\u011fil)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Fc%CE%B3-Rezeptoren_Fc%CE%B3R\" >Fc\u03b3 resept\u00f6rleri (Fc\u03b3R)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neonataler_Fc-Rezeptor_FcRn\" >Yenido\u011fan Fc resept\u00f6r\u00fc (FcRn)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#IL-6-Rezeptor_IL-6R%CE%B1_gp130\" >IL-6 resept\u00f6r\u00fc (IL-6R\u03b1 \/ gp130)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\" >T-h\u00fccresi resept\u00f6r\u00fc (TCR) ve kostim\u00fclasyon molek\u00fclleri<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementrezeptoren\" >Kompleman resept\u00f6rleri<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Histopathologie_und_ZNS-Lasionsmuster\" >Histopatoloji ve MSS lezyon paterni<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Manifestationen_und_Phanotypen\" >Klinik belirtiler ve fenotipler<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Diagnostik\" >Te\u015fhis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutische_Strategien\" >Terap\u00f6tik stratejiler<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Akuttherapie_Schubbehandlung\" >Akut tedavi (n\u00fcks tedavisi)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prophylaktische_Langzeittherapie\" >Profilaktik uzun s\u00fcreli tedavi<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Studien_%E2%80%93_2024%E2%80%932026\" >Klinik \u00e7al\u0131\u015fmalar - 2024-2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neue_und_zukunftige_Therapiekonzepte\" >Yeni ve gelecekteki terapi konseptleri<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#BTK-Inhibitoren_Bruton-Tyrosin-Kinase\" >BTK inhibit\u00f6rleri (Bruton tirozin kinaz)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Toleranzinduktion_MOG-Tolerisierung\" >Tolerans ind\u00fcksiyonu (MOG tolerans\u0131)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementinhibitoren\" >Kompleman inhibit\u00f6rleri<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Anti-Neonatal-Fc-Rezeptor-Strategien\" >Anti-neonatal Fc resept\u00f6r stratejileri<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\" >Otolog hematopoietik k\u00f6k h\u00fccre transplantasyonu (aHSCT)<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Biomarker_und_Verlaufsmonitoring\" >Biyobelirte\u00e7ler ve takip izleme<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prognose_und_Besonderheiten\" >Tahmin ve \u00f6zel \u00f6zellikler<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-49\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zusammenfassung_und_Ausblick\" >\u00d6zet ve genel g\u00f6r\u00fcn\u00fcm<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-50\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\" >U\u00e7ucu ya\u011flar - sinyal yollar\u0131na g\u00f6re s\u0131ralanm\u0131\u015f aktif bile\u015fenler<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-51\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\" >Frankincense (Boswellia serrata) - AKBA ve incensol asetat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-52\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutisch_relevante_AKBA-Zieldosen\" >Terap\u00f6tik olarak ilgili AKBA hedef dozlar\u0131<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-53\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Umrechnung_auf_375_mg_AKBA_jeKapsel\" >Kaps\u00fcl ba\u015f\u0131na 37,5 mg AKBA'ya d\u00f6n\u00fc\u015ft\u00fcrme<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-54\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_Einnahmehinweise\" >\u00d6nemli al\u0131m talimatlar\u0131<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-55\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_oral\" >Karabiber (oral)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-56\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_Inhalation\" >Karabiber (inhalasyon)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-57\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\" >Copaiba ya\u011f\u0131 (oral) - SADECE doTERRA<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-58\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\" >MOGAD'a \u00f6zg\u00fc dozaj tablosu (doTERRA Copaiba 52.5 % BCP)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-59\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-Phasen-adaptierte_Dosierung\" >MOGAD faza uyarlanm\u0131\u015f dozajlama<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-60\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\" >A\u015fama 1: Akut alevlenme (ilk 2-4 hafta)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-61\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_Schubremission_Erhaltung_langfristig\" >A\u015fama 2: n\u00fcks remisyonu \/ idame (uzun s\u00fcreli)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-62\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_Monophasischer_Verlauf_Titer_fallend\" >A\u015fama 3: Monofazik seyir (d\u00fc\u015fen titre)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-63\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen\" >Kaynaklar<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-64\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_Inhalation\" >Copaiba ya\u011f\u0131 (inhalasyon)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-65\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zieldosen_und_benotigte_Tropfenzahl\" >Hedef dozlar ve gerekli damla say\u0131s\u0131<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-66\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Synergistische_MOGAD-Strategie_Multi-Target\" >Sinerjik MOGAD stratejisi (\u00e7oklu hedef)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-67\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_MOGAD-spezifische_Hinweise\" >MOGAD'a \u00f6zg\u00fc \u00f6nemli bilgiler<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-68\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\" >\u03b1-Asaron (kalamus ya\u011f\u0131, Acorus calamus) - do\u011frudan oligodendrosit koruyucu<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-69\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\" >Sardunya ya\u011f\u0131 (Pelargonium graveolens) - n\u00f6roinflamasyon ve NO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-70\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\" >\u00c7ay a\u011fac\u0131 ya\u011f\u0131 (Melaleuca alternifolia) - mikroglia mod\u00fclasyonu<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-71\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wirkstoffubersicht_nach_MOGAD-Signalwegen\" >MOGAD sinyal yollar\u0131na g\u00f6re aktif maddelere genel bak\u0131\u015f<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-72\" href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen_und_weiterfuhrende_Literatur\" >Kaynaklar ve daha fazla okuma<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Okuma s\u00fcresi<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">dakika<\/span><\/span>\n<p class=\"wp-block-paragraph\"><em>Miyelin Oligodendrosit Glikoprotein Antikoru ile \u0130li\u015fkili Hastal\u0131k<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_ist_MOGAD\"><\/span>MOGAD nedir?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Elektrik kablolar\u0131n\u0131 herkes bilir: Kablo demetindeki m\u00fcnferit iletkenleri birbirinden ay\u0131ran yal\u0131t\u0131m ile sa\u011flan\u0131rlar, b\u00f6ylece i\u00e7lerindeki sinyaller birbirine kar\u0131\u015fmaz ve A'dan B'ye bozulmadan ula\u015f\u0131r.<br>Omurilik, bu t\u00fcr bir\u00e7ok kablo demetinden olu\u015fan bir b\u00fct\u00fcn i\u00e7erir. Bunlar beyinden gelen sinir sinyallerini v\u00fccuttaki \u00e7e\u015fitli organlara, kaslara, dokulara vb. iletir. Kablonun yal\u0131t\u0131m\u0131 plastik, tekstil veya \u00f6zel malzemelerden yap\u0131l\u0131rken, omurili\u011fin yal\u0131t\u0131m katman\u0131 \u00f6zel bir malzemeden yap\u0131l\u0131r. <strong>Miyelin tabakas\u0131<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_geht_bei_MOGAD_schief\"><\/span>MOGAD'da yanl\u0131\u015f giden ne?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD durumunda, v\u00fccudun kendi ba\u011f\u0131\u015f\u0131kl\u0131k sistemi ciddi bir hata yapar: yanl\u0131\u015fl\u0131kla <strong>Bu yal\u0131tkan tabakan\u0131n d\u0131\u015f\u0131ndaki belirli bir proteine kar\u015f\u0131 antikorlar<\/strong>, s\u00f6zde. <strong>MOG<\/strong>-protein. Antikorlar asl\u0131nda v\u00fccudun vir\u00fcsler ve bakteriler gibi patojenleri tan\u0131yan, i\u015faretleyen ve yok eden koruyucular\u0131d\u0131r. Ancak MOGAD'da, yanl\u0131\u015fl\u0131kla v\u00fccudun kendi sa\u011fl\u0131kl\u0131 dokusuna, kendi sinir liflerinin yal\u0131t\u0131m\u0131na kar\u015f\u0131 y\u00f6nlendirilirler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bir kabloyla kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, yal\u0131t\u0131m\u0131n \u00e7izilmesi, a\u015f\u0131nd\u0131r\u0131lmas\u0131 veya korozyona u\u011framas\u0131, delikli hale gelmesine ve elektrik sinyallerinin art\u0131k hedeflerine temiz bir \u015fekilde veya hi\u00e7 ula\u015fmamas\u0131na neden olur.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wo_im_Korper_passiert_das\"><\/span>Bu v\u00fccudun neresinde olur?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD m\u00fcnhas\u0131ran a\u015fa\u011f\u0131dakilerle ilgilidir <strong>Merkezi sinir sistemi<\/strong>, Yani beyin, omurilik ve optik sinirler. Hangi b\u00f6lgenin etkilendi\u011fine ba\u011fl\u0131 olarak farkl\u0131 semptomlar ortaya \u00e7\u0131kar:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Optik sinir<\/strong> - Ani g\u00f6rme kayb\u0131, bulan\u0131k g\u00f6rme, g\u00f6z a\u011fr\u0131s\u0131 (genellikle sadece bir g\u00f6zde, bazen her iki g\u00f6zde ayn\u0131 anda - bu MOGAD'da di\u011fer benzer hastal\u0131klara g\u00f6re daha yayg\u0131nd\u0131r)<\/li>\n\n\n\n<li><strong>Omurilik<\/strong> - Fel\u00e7 belirtileri, uyu\u015fukluk, idrar yapma sorunlar\u0131<\/li>\n\n\n\n<li><strong>Beyin:<\/strong> Konf\u00fczyon, epileptik n\u00f6betler, koordinasyon bozukluklar\u0131<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_verlauft_die_Erkrankung\"><\/span>Hastal\u0131k nas\u0131l ilerliyor?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD tipik olarak \u015fu \u015fekilde ilerler <strong>\u0130tiyor<\/strong>. Enflamasyonun aktif oldu\u011fu ve semptomlar\u0131n ortaya \u00e7\u0131kt\u0131\u011f\u0131 evreler vard\u0131r, arada daha sakin evreler vard\u0131r.<br>Bir ataktan sonra, bir\u00e7ok hasta \u015fa\u015f\u0131rt\u0131c\u0131 derecede iyi iyile\u015fir, \u00f6rne\u011fin MS'ten daha iyidir. Bunun nedeni, sinir liflerinin kendilerinin, k\u0131smen yenilenebilen yal\u0131t\u0131m tabakas\u0131ndan daha az kal\u0131c\u0131 hasar g\u00f6rme olas\u0131l\u0131\u011f\u0131n\u0131n olmas\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Etkilenenlerin yakla\u015f\u0131k yar\u0131s\u0131 ya\u015famlar\u0131 boyunca sadece tek bir alevlenme ya\u015far. Di\u011fer yar\u0131s\u0131nda ise tekrarlayan ataklar g\u00f6r\u00fcl\u00fcr ve bu durum tedavi edilmedi\u011fi takdirde kal\u0131c\u0131 bozukluklara yol a\u00e7abilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_haufig_ist_MOGAD\"><\/span>MOGAD ne kadar yayg\u0131nd\u0131r?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD nadirdir, sadece tahmin edilmektedir <strong>100.000 ki\u015fiden 1-2'si<\/strong> hasta olurlar. Sinir sisteminin di\u011fer bir\u00e7ok otoimm\u00fcn hastal\u0131\u011f\u0131ndan farkl\u0131 olarak, kad\u0131nlar\u0131 ve erkekleri kabaca e\u015fit say\u0131da etkiler. Genellikle kafa kar\u0131\u015f\u0131kl\u0131\u011f\u0131 ve ate\u015fle birlikte beyinde yayg\u0131n bir iltihaplanma \u015feklinde kendini g\u00f6steren bu hastal\u0131\u011fa \u00e7ocuklar da yakalanabilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_lost_MOGAD_aus\"><\/span>MOGAD'\u0131 ne tetikler?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130lk b\u00f6l\u00fcm\u00fcn ard\u0131ndan genellikle <strong>Enfeksiyon<\/strong> ileride. V\u00fccut bir patojene kar\u015f\u0131 sava\u015f\u0131r ve yanl\u0131\u015fl\u0131kla v\u00fccudun kendi yap\u0131lar\u0131n\u0131 d\u00fc\u015fmanla kar\u0131\u015ft\u0131r\u0131r. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemi tabiri caizse yanl\u0131\u015f hedefe sald\u0131rmay\u0131 \u00f6\u011frenir ve asla durmaz. Kesin nedeni hen\u00fcz tam olarak anla\u015f\u0131lamam\u0131\u015ft\u0131r. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_wird_MOGAD_behandelt\"><\/span>MOGAD nas\u0131l tedavi edilir?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eu anda MOGAD i\u00e7in \u00f6zel olarak ruhsatland\u0131r\u0131lm\u0131\u015f bir ila\u00e7 bulunmamaktad\u0131r. Bir <strong>akut atak<\/strong> y\u00fcksek dozda ila\u00e7 ile tedavi edilir. <strong>Kortizon inf\u00fczyonlar\u0131<\/strong>, Bu da iltihab\u0131 h\u0131zla azalt\u0131r. E\u011fer bu yeterli de\u011filse <strong>Kan y\u0131kama<\/strong> (<em>Plazmaferez<\/em>) zararl\u0131 antikor do\u011frudan kandan uzakla\u015ft\u0131r\u0131labilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u015euraya <strong>Daha fazla n\u00fcks\u00fcn \u00f6nlenmesi<\/strong> Ba\u011f\u0131\u015f\u0131kl\u0131k sistemini sakinle\u015ftirmek i\u00e7in, \u00f6rne\u011fin antikor \u00fcreten h\u00fccreleri azaltan maddeler gibi \u00e7e\u015fitli ila\u00e7lar kullan\u0131lmaktad\u0131r. Birka\u00e7 yeni, daha hedefe y\u00f6nelik ila\u00e7 \u015fu anda klinik deneylerde test edilmektedir ve \u00f6n\u00fcm\u00fczdeki birka\u00e7 y\u0131l i\u00e7inde ruhsatland\u0131r\u0131labilir.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wissenschaftliche_Einleitung_und_Definition\"><\/span>Bilimsel giri\u015f ve tan\u0131m<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Bu <strong>MOG antikoru ile ili\u015fkili hastal\u0131k (MOGAD)<\/strong> \u0130ngilizce: <em>Miyelin Oligodendrosit Glikoprotein Antikoru ile \u0130li\u015fkili Hastal\u0131k<\/em> merkezi sinir sisteminin (MSS) nadir g\u00f6r\u00fclen, enflamatuar otoimm\u00fcn bir hastal\u0131\u011f\u0131d\u0131r ve 2018'den beri kendi tan\u0131 kriterlerine sahip ba\u011f\u0131ms\u0131z bir varl\u0131k olarak kabul edilmektedir. Daha \u00f6nce multipl skleroz (MS) veya n\u00f6romiyelitis optika spektrum bozuklu\u011funun (NMOSD) bir varyant\u0131 olarak kabul ediliyordu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hastal\u0131\u011f\u0131n temel unsuru, patolojik olarak otoantikor (IgG) \u00fcretilmesidir. <strong>Miyelin oligodendrosit glikoproteini (MOG)<\/strong>, MSS'deki oligodendrositlerin miyelin k\u0131l\u0131f\u0131n\u0131n en d\u0131\u015f katman\u0131nda bulunan bir transmembran proteini. Bu antikorlar miyelin k\u0131l\u0131flar\u0131na zarar verir ve karakteristik periven\u00fcler demiyelinizasyona yol a\u00e7ar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik olarak, MOGAD esas olarak optik n\u00f6rit, transvers miyelit ve akut dissemine ensefalomiyelit (ADEM) olarak kendini g\u00f6sterir. Hastal\u0131k genellikle n\u00fckseder ve optik sinir, omurilik ve daha nadiren beyni etkiler. Ortalama ba\u015flang\u0131\u00e7 ya\u015f\u0131 30 ila 35 aras\u0131ndad\u0131r; NMOSD'nin aksine, kad\u0131nlar ve erkekler neredeyse e\u015fit s\u0131kl\u0131kta etkilenir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Abgrenzung_von_MOGAD_NMOSD_und_MS\"><\/span>MOGAD, NMOSD ve MS aras\u0131ndaki farkl\u0131la\u015fma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>\u00d6zellik<\/strong><\/td><td><strong>MOGAD<\/strong><\/td><td><strong>AQP4+ NMOSD<\/strong><\/td><td><strong>Multipl skleroz<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Hedef antijen<\/td><td>MOG (oligodendrositler)<\/td><td>Aquaporin-4 (astrositler)<\/td><td>Spesifik otoantikor yok<\/td><\/tr><tr><td>Antikor izotipi<\/td><td>IgG1 (\u00f6n)<\/td><td>IgG1 (\u00f6n)<\/td><td>Oligoklonal IgG (BOS)<\/td><\/tr><tr><td>Birincil h\u00fccre hasar\u0131<\/td><td>Oligodendrositler\/myelin<\/td><td>Astrositler (birincil)<\/td><td>Oligodendrositler<\/td><\/tr><tr><td>Histoloji<\/td><td>Periven\u00fcler demiyelinizasyon, CD4+<\/td><td>Astrosit lezyonlar\u0131, gran\u00fclositler<\/td><td>Periaksiyel plaklar<\/td><\/tr><tr><td>Cinsiyet (K:E)<\/td><td>~1:1<\/td><td>~9:1<\/td><td>~3:1<\/td><\/tr><tr><td>Kompleman aktivasyonu<\/td><td>Orta (daha az MAC)<\/td><td>G\u00fc\u00e7l\u00fc (MAC olu\u015fumu)<\/td><td>D\u00fc\u015f\u00fck<\/td><\/tr><tr><td>Beyin omurilik s\u0131v\u0131s\u0131nda OKB<\/td><td>Nadir (&lt;10%)<\/td><td>Ara s\u0131ra<\/td><td>S\u0131k (&gt;90%)<\/td><\/tr><tr><td>Kurs<\/td><td>N\u00fckseden; genellikle iyi iyile\u015fmi\u015f<\/td><td>\u0130tme \u015feklinde; sakatl\u0131k biriktirir<\/td><td>Genellikle progedient<\/td><\/tr><tr><td>\u0130zinli tedaviler<\/td><td>Yok (2026 itibariyle)<\/td><td>Eculizumab, ublituximab, satralizumab<\/td><td>Bir\u00e7ok DMT<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\"><\/span>MOG proteini - yap\u0131s\u0131 ve fizyolojik i\u015flevi<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOG (miyelin oligodendrosit glikoproteini) bir <strong>Tip I transmembran protein<\/strong> Toplam uzunlu\u011fu 218 amino asit olan bu protein sadece MSS'de eksprese edilir. \u0130mm\u00fcnoglobulin s\u00fcper ailesinin bir \u00fcyesidir ve toplam miyelin proteininin yakla\u015f\u0131k 0.01-0.05 %'lik bir oran\u0131yla, miyelin k\u0131l\u0131f\u0131n\u0131n niceliksel olarak k\u00fc\u00e7\u00fck ancak imm\u00fcnolojik olarak olduk\u00e7a ilgili bir bile\u015fenini temsil eder.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Strukturdomanen\"><\/span>Yap\u0131sal alanlar<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ekstrasel\u00fcler Ig-V benzeri alan (AS 1-120): Tek a\u00e7\u0131k alan, y\u00fcksek imm\u00fcnojenik; MOG-IgG i\u00e7in en \u00f6nemli epitop ba\u011flanma b\u00f6lgesi olarak kritik CC\u2018 d\u00f6ng\u00fc b\u00f6lgesini (Pro42, His103, Ser104) i\u00e7erir<\/li>\n\n\n\n<li>Tek ge\u00e7i\u015fli transmembran sarmal: Proteini miyelin membran\u0131na sabitler<\/li>\n\n\n\n<li>K\u0131sa sitoplazmik C-terminal alan\u0131: muhtemelen h\u00fccre iskeleti ile etkile\u015fime girer<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Physiologische_Funktionen\"><\/span>Fizyolojik i\u015flevler<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Yap\u0131\u015fma molek\u00fcl\u00fc: Muhtemelen miyelin lamellerini s\u0131k\u0131\u015ft\u0131rarak miyelin k\u0131l\u0131f\u0131n\u0131n yap\u0131sal b\u00fct\u00fcnl\u00fc\u011f\u00fcne arac\u0131l\u0131k eder<\/li>\n\n\n\n<li>Kompleman sisteminin C1q'su ile etkile\u015fim (fizyolojik)<\/li>\n\n\n\n<li>Sinir b\u00fcy\u00fcme fakt\u00f6r\u00fc (NGF) ile etkile\u015fim<\/li>\n\n\n\n<li>K\u0131zam\u0131k\u00e7\u0131k vir\u00fcs\u00fc i\u00e7in resept\u00f6r (klinik olarak enfeksiyon sonras\u0131 ADEM ile ilgili)<\/li>\n\n\n\n<li>Oligodendrositlerde mikrot\u00fcb\u00fcllerin stabilizasyonu<\/li>\n\n\n\n<li>Ekspresyon: Oligodendrosit farkl\u0131la\u015fmas\u0131nda ge\u00e7; sadece ilk miyelinle\u015fmeden sonra<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">MOG-IgG otoantikorlar\u0131 \u00f6ncelikle \u015funlar\u0131 tan\u0131r <strong>Konformasyonel epitoplar<\/strong> h\u00fccre d\u0131\u015f\u0131 alan\u0131n. MOG, miyelin k\u0131l\u0131f\u0131n\u0131n en d\u0131\u015f y\u00fczeyinde a\u00e7\u0131\u011fa \u00e7\u0131kt\u0131\u011f\u0131 i\u00e7in, dola\u015f\u0131mdaki antikorlar ve ba\u011f\u0131\u015f\u0131kl\u0131k kompleksleri taraf\u0131ndan do\u011frudan eri\u015filebilir - h\u00fccre i\u00e7i antijenlere g\u00f6re belirleyici bir fark.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pathogenese_und_Immunpathologie\"><\/span>Patogenez ve imm\u00fcnopatoloji<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD patogenezi, periferik imm\u00fcn aktivasyon, kan-beyin bariyerini (BBB) a\u015fan g\u00f6\u00e7 ve MSS-lokal efekt\u00f6r mekanizmalar\u0131n\u0131 i\u00e7eren \u00e7ok a\u015famal\u0131 bir s\u00fcre\u00e7tir. Ne T h\u00fccreleri ne de B h\u00fccreleri tek ba\u015f\u0131na yeterince patojenik de\u011fildir, hastal\u0131\u011fa neden olan adaptif ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin her iki kolunun sinerjik etkile\u015fimidir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Trigger_und_initiale_Aktivierung\"><\/span>Tetikleme ve ilk aktivasyon<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u015fl\u0131ca ilk tetikleyiciler \u015funlard\u0131r <strong>Enfeksiyonlar<\/strong> tart\u0131\u015f\u0131lm\u0131\u015ft\u0131r: MOGAD hastalar\u0131n\u0131n 37-70 %'sinde enfeksiy\u00f6z bir prodrom belgelenmi\u015ftir (15-35 % ile NMOSD'den daha s\u0131k). Mekanizmalar \u015funlar\u0131 i\u00e7erir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Molek\u00fcler taklit - patojen epitoplar\u0131 yap\u0131sal olarak MOG'nin CC\u2018 loop b\u00f6lgesine benzer, \u00f6rne\u011fin SARS-CoV-2 sekanslar\u0131 veya k\u0131zam\u0131k\u00e7\u0131k vir\u00fcsleri<\/li>\n\n\n\n<li>Seyirci aktivasyonu - spesifik olmayan enflamatuar reaksiyon, uykuda olan otoreaktif lenfositleri aktive eder<\/li>\n\n\n\n<li>Mikrobiyal s\u00fcperantijenlerle poliklonal B-h\u00fccresi aktivasyonu<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Genetik yatk\u0131nl\u0131k bir rol oynamaktad\u0131r, ancak spesifik risk haplotipleri kesin olarak tan\u0131mlanmam\u0131\u015ft\u0131r. MS'in aksine, tutarl\u0131 bir HLA ili\u015fkisi tan\u0131mlanmam\u0131\u015ft\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-vermittelte_Pathogenese\"><\/span>T-h\u00fccresi arac\u0131l\u0131 patogenez<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOG-spesifik CD4+ T h\u00fccreleri MOGAD patogenezi i\u00e7in gereklidir. Hayvan modellerinde (EAE), antikorlar tek ba\u015f\u0131na patojenik de\u011fildir; yard\u0131mc\u0131 efekt\u00f6r olarak ensefalitojenik T h\u00fccrelerine ihtiya\u00e7 duyarlar. CD4+ yolu birka\u00e7 a\u015famadan olu\u015fmaktad\u0131r:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_%E2%80%93_Periphere_Aktivierung\"><\/span>A\u015fama 1 - Periferik aktivasyon<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOG peptidleri, antijen sunan h\u00fccreler (APC) taraf\u0131ndan \u015fu yollarla \u00fcretilir <strong>MHC-II molek\u00fclleri<\/strong> Naif CD4+ T h\u00fccrelerine. Dikkate de\u011fer: <em>MOG peptidleri do\u011frudan periferik MHC II molek\u00fcllerine ba\u011flanabilir<\/em>, daha fazla i\u015flem g\u00f6rmeden. Bu durum, periferik sinir sisteminin kat\u0131l\u0131m\u0131n\u0131 a\u00e7\u0131klayabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Birbirinden ba\u011f\u0131ms\u0131z olarak EAE'yi ind\u00fckleyebilen efekt\u00f6r h\u00fccre alt k\u00fcmeleri \u015funlard\u0131r <strong>Th1, Th17 ve Th9<\/strong>. Th17 h\u00fccreleri \u00f6zellikle MOGAD ile ilgilidir, \u00e7\u00fcnk\u00fc Th17 sitokinleri (IL-17, IL-21) kesme olaylar\u0131 s\u0131ras\u0131nda belirgin \u015fekilde y\u00fckselir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_%E2%80%93_BHS-Penetration\"><\/span>A\u015fama 2 - BHS penetrasyonu<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Aktive olmu\u015f CD4+ T h\u00fccreleri spesifik adezyon molek\u00fcllerini (integrinler, selektinler) ve kemokin resept\u00f6rlerini (\u00f6zellikle <strong>CCR6<\/strong>), MSS'ye girmelerini sa\u011flar. CCR6+ Th17 h\u00fccreleri, koroid pleksusta yap\u0131sal olarak ifade edilen CCL20'ye ba\u011flan\u0131r ve bunun arac\u0131l\u0131\u011f\u0131yla subaraknoid bo\u015flu\u011fa girer.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Matris metalloproteinazlar (MMP-2, MMP-9)<br>BBB'nin bazal membran\u0131n\u0131n bozulmas\u0131<\/li>\n\n\n\n<li>N\u00f6trofil NET'leri (N\u00f6trofil Ekstrasel\u00fcler Tuzaklar\u0131)<br>Ba\u015flang\u0131\u00e7 a\u015famas\u0131ndaki T h\u00fccreleri i\u00e7in kostim\u00fclat\u00f6r sinyaller sa\u011flar<\/li>\n\n\n\n<li>Trombositler<br>Sitokinler ve adezyon molek\u00fclleri arac\u0131l\u0131\u011f\u0131yla CD4+ T h\u00fccre \u00e7o\u011falmas\u0131n\u0131 ve Th1\/Th17'ye farkl\u0131la\u015fmas\u0131n\u0131 te\u015fvik eder<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\"><\/span>A\u015fama 3 - Perivask\u00fcler reaktivasyon<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Perivask\u00fcler bo\u015flukta ve subaraknoid bo\u015flukta, MOG-spesifik T h\u00fccreleri yerel MOG y\u00fckl\u00fc APC'ler (mikroglia, dendritik h\u00fccreler) taraf\u0131ndan yeniden aktive edilir. Bu reaktivasyon as\u0131l enflamatuar kaskad\u0131 tetikler: Proinflamatuar sitokinlerin salg\u0131lanmas\u0131, daha fazla l\u00f6kositin toplanmas\u0131 ve oligodendrosit hasar\u0131.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"B-Zell-_und_Antikorper-vermittelte_Pathogenese\"><\/span>B-h\u00fccresi ve antikor arac\u0131l\u0131 patogenez<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOG-spesifik B h\u00fccreleri ve plazma h\u00fccreleri patojenik IgG1 otoantikorlar\u0131n\u0131n ana \u00fcreticileridir. Bununla birlikte, B h\u00fccresinin rol\u00fc antikor \u00fcretiminin \u00f6tesine ge\u00e7er:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Antijen sunumu - B h\u00fccreleri, BCR'leri arac\u0131l\u0131\u011f\u0131yla MOG konformasyonel epitoplar\u0131n\u0131 (pro42, his103, CC\u2018 d\u00f6ng\u00fcs\u00fcn\u00fcn ser104'\u00fc) ba\u011flayabilir ve T h\u00fccreleri i\u00e7in APC olarak hareket edebilir<\/li>\n\n\n\n<li>Th17 farkl\u0131la\u015fmas\u0131n\u0131n te\u015fvik edilmesi - B h\u00fccreleri IL-6 salg\u0131lar, bu da TGF-\u03b2 ile birlikte Th17 farkl\u0131la\u015fmas\u0131n\u0131 y\u00f6nlendirir<\/li>\n\n\n\n<li>MAPK ve AKT sinyal aktivasyonu - MOG'a BCR ba\u011flanmas\u0131 bu sinyal yollar\u0131n\u0131 h\u00fccre i\u00e7inde aktive eder<\/li>\n\n\n\n<li>H\u00fccre i\u00e7i kalsiyum art\u0131\u015f\u0131 - Stresle ili\u015fkili sinyal kaskadlar\u0131n\u0131n aktivasyonuna yol a\u00e7ar<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">MOG-IgG antikorlar\u0131n\u0131n \u00e7o\u011fu periferde \u00fcretilir (BOS'ta oligoklonal bantlar sadece vakalar\u0131n ~10 %'sinde, kar\u015f\u0131la\u015ft\u0131rma: MS ~90 %). Antikorlar <strong>bivalent-ba\u011flay\u0131c\u0131<\/strong> MOG'a ba\u011fland\u0131\u011f\u0131nda, her iki Fab kolu ayn\u0131 anda iki kom\u015fu MOG molek\u00fcl\u00fcne ba\u011flan\u0131r. Bu, NMOSD'de AQP4-IgG'nin monovalent ba\u011flanmas\u0131na k\u0131yasla daha az etkili C1q al\u0131m\u0131na yol a\u00e7ar.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molekulare_Signalwege_und_Effektormechanismen\"><\/span>Molek\u00fcler sinyal yollar\u0131 ve efekt\u00f6r mekanizmalar\u0131<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\"><\/span>Sinyalizasyon yolu 1 - klasik kompleman yolu (CDC)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOG-IgG1 (ve MOG-IgG3) oligodendrosit MOG'a ba\u011fland\u0131\u011f\u0131nda <strong>klasik tamamlay\u0131c\u0131 rota<\/strong> aktive edilir. Ancak, MOGAD'da kompleman aktivasyonu AQP4+ NMOSD'ye g\u00f6re daha zay\u0131ft\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ba\u011fl\u0131 IgG1 antikorlar\u0131n\u0131n Fc k\u0131sm\u0131na C1q ba\u011flanmas\u0131 \u2192 C1r ve C1s aktivasyonu<\/li>\n\n\n\n<li>C4 \u2192 C4a + C4b b\u00f6l\u00fcnmesi; C4b + C2 \u2192 C3 konvertaz (C4b2a)<\/li>\n\n\n\n<li>C3'\u00fcn b\u00f6l\u00fcnmesi \u2192 C3a (anafilatoksin) + C3b (opsonin)<\/li>\n\n\n\n<li>C3b \u2192 C5 konvertaz \u2192 C5'in b\u00f6l\u00fcnmesi \u2192 C5a (g\u00fc\u00e7l\u00fc anafilatoksin) + C5b<\/li>\n\n\n\n<li>C5b + C6, C7, C8, C9 \u2192 membran sald\u0131r\u0131 kompleksi (MAC, C5b-9): Oligodendrositlerin do\u011frudan par\u00e7alanmas\u0131<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u00d6nemli: MOGAD hastalar\u0131n\u0131n BOS'unda C3a ve C5a \u00f6nemli \u00f6l\u00e7\u00fcde artm\u0131\u015ft\u0131r (AQP4+ NMOSD ile kar\u015f\u0131la\u015ft\u0131r\u0131labilir), ancak MAC kompleksi (C5b-9) \u00f6nemli \u00f6l\u00e7\u00fcde artmam\u0131\u015ft\u0131r. <strong>\u00f6nemli \u00f6l\u00e7\u00fcde daha d\u00fc\u015f\u00fck<\/strong> NMOSD'ye k\u0131yasla. Bunun nedeni, C1q k\u00fcmelenmesi i\u00e7in daha az etkili olan bivalent IgG ba\u011flanmas\u0131 ve oligodendrositler \u00fczerindeki nispeten d\u00fc\u015f\u00fck kompleman d\u00fczenleyici yo\u011funlu\u011fudur (di\u011fer h\u00fccre tiplerine g\u00f6re daha az CR1, MCP, HRF).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\"><\/span>Sinyalizasyon yolu 2 - Fc\u03b3 resept\u00f6r yolu (FcR arac\u0131l\u0131)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">LMU ara\u015ft\u0131rmas\u0131 (Mader, Kawakami, Meinl, 2024 PNAS), Fc\u03b3 resept\u00f6r\u00fc (Fc\u03b3R) arac\u0131l\u0131 mekanizmalar\u0131n <strong>miyelin hasar\u0131n\u0131n yakla\u015f\u0131k 50 %'sine<\/strong> ve bu nedenle kompleman aktivasyonu ile ayn\u0131 seviyededir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RIII<\/strong> (<strong>CD16<\/strong>) NK h\u00fccreleri ve makrofajlar \u00fczerinde<br>MOG-ba\u011fl\u0131 IgG1'in Fc k\u0131sm\u0131n\u0131 ba\u011flar \u2192 ADCC (antikora ba\u011fl\u0131 h\u00fccresel sitotoksisite)<\/li>\n\n\n\n<li><strong>Fc\u03b3RI\/II\/III<\/strong> makrofajlar ve monositler \u00fczerinde<br>MOG-opsonize oligodendrosit fragmanlar\u0131n\u0131n fagositozu (ADCP)<\/li>\n\n\n\n<li>Belirleyici: \u0130kinci FcR patomekanizmas\u0131<br>T-h\u00fccresi aktivasyonunun art\u0131r\u0131lmas\u0131, kompleman yolu \u00fczerinden DE\u011e\u0130L, yaln\u0131zca Fc resept\u00f6rleri \u00fczerinden \u00e7al\u0131\u015f\u0131r<\/li>\n\n\n\n<li><strong>Fc\u03b3R<\/strong> dendritik h\u00fccreler \u00fczerinde<br>MOG-IgG y\u00fckl\u00fc oligodendrosit antijenlerinin MOG-spesifik T h\u00fccrelerine i\u015flenmesini ve sunumunu kolayla\u015ft\u0131rmak<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik anlam\u0131: \u0130ki ba\u011f\u0131ms\u0131z patojenik yolak mevcut oldu\u011fundan, terap\u00f6tik yakla\u015f\u0131mlar <strong>Her iki mekanizma<\/strong> maksimum etkinlik elde etmek i\u00e7in.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\"><\/span>Sinyalizasyon yolu 3 - IL-6\/JAK-STAT3 yolu<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">IL-6, MOGAD imm\u00fcnopatogenezinin merkezi bir arac\u0131s\u0131d\u0131r ve \u00e7e\u015fitli d\u00fczeylerde etki g\u00f6sterir:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">IL-6 resept\u00f6r\u00fcne (IL-6R\u03b1\/gp130 kompleksi) ba\u011flan\u0131r ve bu da <strong>JAK1\/2 fosforilasyonu<\/strong> yol a\u00e7ar. Bu \u00f6ncelikle \u015funlar\u0131 etkinle\u015ftirir <strong>STAT3<\/strong>, i\u00e7in bir transkripsiyon fakt\u00f6r\u00fc olarak hizmet eder:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17 farkl\u0131la\u015fmas\u0131<\/strong><br>IL-6 + TGF-\u03b2 \u2192 ROR\u03b3t ifadesi \u2192 IL-17A\/F \u00fcretimi; IL-6 + IL-23 \u2192 Th17 fenotipinin s\u00fcrd\u00fcr\u00fclmesi<\/li>\n\n\n\n<li><strong>Folik\u00fcler T yard\u0131mc\u0131 h\u00fccreleri<\/strong> (<strong>Tfh<\/strong>)<br>IL-6 \u2192 STAT3 \u2192 Bcl6 ifadesi \u2192 Germinal merkez B h\u00fccre olgunla\u015fmas\u0131 ve IgG s\u0131n\u0131f de\u011fi\u015fimi<\/li>\n\n\n\n<li><strong>Plazma h\u00fccrelerine B-h\u00fccresi olgunla\u015fmas\u0131<\/strong><br>IL-6, STAT3\/Blimp-1 ekseni arac\u0131l\u0131\u011f\u0131yla farkl\u0131la\u015fmay\u0131 te\u015fvik eder<\/li>\n\n\n\n<li><strong>Treg fonksiyonunun bask\u0131lanmas\u0131<\/strong><br>IL-6 FoxP3 ekspresyonunu inhibe ederek Treg\/Th17 dengesini enflamasyona do\u011fru kayd\u0131r\u0131r<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Terap\u00f6tik \u00f6nem: IL-6 blokaj\u0131 (\u00f6rn. tocilizumab, satralizumab) bu d\u00f6ng\u00fcy\u00fc k\u0131rar. <strong><em>Satralizumab<\/em><\/strong> (anti-IL-6R) \u015fu anda MOGAD i\u00e7in Faz 3 METEOROID \u00e7al\u0131\u015fmas\u0131nda ara\u015ft\u0131r\u0131lmaktad\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\"><\/span>Sinyalizasyon yolu 4 - MAPK ve AKT sinyalizasyon yollar\u0131 (B h\u00fccreleri)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">B h\u00fccrelerinde aktive edilen MOG konformasyonel epitoplar\u0131na BCR ba\u011flanmas\u0131:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MAPK yolu<\/strong> (<strong>MEK\/ERK<\/strong>)<br>B-h\u00fccresi proliferasyonunun ve farkl\u0131la\u015fmas\u0131n\u0131n te\u015fvik edilmesi<\/li>\n\n\n\n<li><strong>PI3K\/AKT yolu<\/strong><br>H\u00fccre sa\u011fkal\u0131m\u0131 ve B h\u00fccrelerinin plazma h\u00fccrelerine farkl\u0131la\u015fmas\u0131<\/li>\n\n\n\n<li><strong>Kalsiyum ak\u0131\u015f\u0131<\/strong><br>Kalsin\u00f6rin\/NFAT ekseninin aktivasyonu \u2192 Sitokin \u00fcretimi<\/li>\n\n\n\n<li><strong>NK h\u00fccre aktivasyonu<\/strong><br>BCR-MOG ba\u011flanmas\u0131 NK h\u00fccre arac\u0131l\u0131 sitotoksisiteyi tetikler<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\"><\/span>Sinyalizasyon yolu 5 - MSS'de Th17 sitokin a\u011f\u0131<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MSS'de, Th17 h\u00fccreleri \u00e7oklu arac\u0131lar yoluyla enflamatuar bir ortam sa\u011flar:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-17A ve IL-17F<\/strong><br>Astrositleri ve mikroglialar\u0131 aktive eder; n\u00f6trofilleri toplayan kemokinlerin (CXCL-1\/5\/8) sal\u0131n\u0131m\u0131n\u0131 ind\u00fckler<\/li>\n\n\n\n<li><strong>IL-21<\/strong> (oto- ve parakrin)<br>Th17 farkl\u0131la\u015fmas\u0131n\u0131 art\u0131r\u0131r; B-h\u00fccresi farkl\u0131la\u015fmas\u0131n\u0131 ve IgG s\u0131n\u0131f de\u011fi\u015fimini (\u00f6zellikle IgG1) destekler<\/li>\n\n\n\n<li><strong>IL-22<\/strong><br>BBB b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fcn d\u00fczensizli\u011fi<\/li>\n\n\n\n<li><strong>GM-CSF<\/strong> (<strong>IL-23 arac\u0131l\u0131\u011f\u0131yla<\/strong>)<br>Mikroglia ve makrofajlar\u0131 aktive eder, lokal demiyelinizasyonu art\u0131r\u0131r<\/li>\n\n\n\n<li><strong>CXCL13<\/strong><br>Perivask\u00fcler bo\u015fluklarda B h\u00fccrelerinin kemotaksisi \u2192 lokal antikor \u00fcretimi<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalwege_%E2%80%93_Ubersicht\"><\/span>Sinyalizasyon yollar\u0131 - genel bak\u0131\u015f<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Sinyal yolu<\/strong><\/td><td><strong>Anahtar molek\u00fcller<\/strong><\/td><td><strong>Etki<\/strong><\/td><td><strong>Terap\u00f6tik hedefler<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Klasik tamamlay\u0131c\u0131 rota<\/td><td>C1q, C3, C5, MAC (C5b-9)<\/td><td>Do\u011frudan oligodendrosit lizisi<\/td><td>C5 inhibit\u00f6rleri (eculizumab), C3 inhibit\u00f6rleri<\/td><\/tr><tr><td>Fc\u03b3R yolu (ADCC\/ADCP)<\/td><td>Fc\u03b3RI\/II\/III, NK h\u00fccreleri, makrofajlar<\/td><td>Sitotoksisite, fagositoz, T-h\u00fccre g\u00fc\u00e7lenmesi<\/td><td>FcRn inhibit\u00f6rleri (IgG degradasyonu), FcR blokaj\u0131<\/td><\/tr><tr><td>IL-6\/JAK-STAT3<\/td><td>IL-6, IL-6R\u03b1, gp130, JAK1\/2, STAT3, ROR\u03b3t<\/td><td>Th17 farkl\u0131la\u015fmas\u0131, B-h\u00fccresi olgunla\u015fmas\u0131, IgG \u00fcretimi<\/td><td>Anti-IL-6R (tocilizumab, satralizumab)<\/td><\/tr><tr><td>PI3K\/AKT\/MAPK (B h\u00fccreleri)<\/td><td>BTK, PI3K, AKT, ERK, NFAT<\/td><td>B-h\u00fccresi aktivasyonu, plazma h\u00fccresi olgunla\u015fmas\u0131<\/td><td>BTK inhibit\u00f6rleri (ibrutinib, tolebrutinib)<\/td><\/tr><tr><td>Th17 sitokin a\u011f\u0131<\/td><td>IL-17, IL-21, IL-22, GM-CSF, CXCL13<\/td><td>BBB hasar\u0131, l\u00f6kosit al\u0131m\u0131, demiyelinizasyon<\/td><td>Anti-IL-17, Anti-IL-21<\/td><\/tr><tr><td>FcRn-IgG geri d\u00f6n\u00fc\u015f\u00fcm\u00fc<\/td><td>FcRn (neonatal Fc resept\u00f6r\u00fc)<\/td><td>Uzam\u0131\u015f IgG yar\u0131 \u00f6mr\u00fc<\/td><td>Anti-FcRn (rozanolixizumab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Relevante_Rezeptoren_und_Zielmolekule\"><\/span>\u0130lgili resept\u00f6rler ve hedef molek\u00fcller<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\"><\/span>Hedef yap\u0131 olarak MOG'un kendisi (klasik bir resept\u00f6r de\u011fil)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD'da, MOG proteini bir sinyal resept\u00f6r\u00fc olarak de\u011fil, bir antijen olarak hareket eder. Bununla birlikte, a\u015fa\u011f\u0131daki etkile\u015fimler patofizyolojik olarak \u00f6nemlidir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C1q ba\u011flanmas\u0131<\/strong><br>MOG fizyolojik olarak C1q'yu ba\u011flayabilir, bu da patolojik antikor kapsam\u0131 durumunda kompleman aktivasyonuna yol a\u00e7ar<\/li>\n\n\n\n<li><strong>DC-SIGN (CD209)<\/strong><br>Dendritik h\u00fccreler \u00fczerindeki lektin resept\u00f6r\u00fc; MOG'yi ba\u011flayabilir ve antijen sunumuna katk\u0131da bulunabilir<\/li>\n\n\n\n<li><strong>K\u0131zam\u0131k\u00e7\u0131k vir\u00fcs\u00fc resept\u00f6r\u00fc<\/strong>_<br>MOG, k\u0131zam\u0131k\u00e7\u0131k vir\u00fcsleri i\u00e7in bir giri\u015f molek\u00fcl\u00fc olarak g\u00f6rev yapar ve bu da \u00e7ocuklarda enfeksiyon sonras\u0131 ADEM'i a\u00e7\u0131klayabilir<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fc%CE%B3-Rezeptoren_Fc%CE%B3R\"><\/span>Fc\u03b3 resept\u00f6rleri (Fc\u03b3R)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccreleri \u00fczerindeki Fc\u03b3 resept\u00f6rleri, IgG1 arac\u0131l\u0131 hasar\u0131n merkezi efekt\u00f6rleridir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RI (CD64)<\/strong><br>Y\u00fcksek afinite, makrofajlar ve dendritik h\u00fccreler \u00fczerinde; ADCP ve antijen sunumuna arac\u0131l\u0131k<\/li>\n\n\n\n<li><strong>Fc\u03b3RIII (CD16)<\/strong><br>D\u00fc\u015f\u00fck afiniteli, NK h\u00fccrelerinde; MOG-opsonize oligodendrositlere kar\u015f\u0131 ADCC'nin ana arac\u0131s\u0131<\/li>\n\n\n\n<li><strong>Fc\u03b3RIIA\/B (CD32A\/B)<\/strong><br>Aktifle\u015ftirme veya inhibe etme; B-h\u00fccresi aktivasyonu ve fagositoz mod\u00fclasyonu<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neonataler_Fc-Rezeptor_FcRn\"><\/span>Yenido\u011fan Fc resept\u00f6r\u00fc (FcRn)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">FcRn (\u03b22m\/FcRn-\u03b1 kompleksi) IgG antikorlar\u0131n\u0131n h\u00fccre i\u00e7i geri d\u00f6n\u00fc\u015f\u00fcm\u00fcnden sorumludur. IgG'yi asitlenmi\u015f endozomlarda (pH 6.0) ba\u011flar ve lizozomal bozunmas\u0131n\u0131 \u00f6nleyerek IgG yar\u0131 \u00f6mr\u00fcn\u00fc yakla\u015f\u0131k 21 g\u00fcne uzat\u0131r.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>MOGAD'da FcRn, patojenik MOG-IgG1'in kal\u0131c\u0131 dola\u015f\u0131m\u0131na neden olur<\/li>\n\n\n\n<li>A\u015fa\u011f\u0131dakilere ba\u011fl\u0131 terap\u00f6tik blokaj <em>Rozanolixizumab<\/em> (anti-FcRn IgG4): Lizozomal IgG degradasyonunu zorlar ve plazma IgG'sini ~50% d\u00fc\u015f\u00fcr\u00fcr<\/li>\n\n\n\n<li>FcRn ekspresyonu - epitel h\u00fccreleri, endotel h\u00fccreleri, monositler, hepatositler<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IL-6-Rezeptor_IL-6R%CE%B1_gp130\"><\/span>IL-6 resept\u00f6r\u00fc (IL-6R\u03b1 \/ gp130)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">IL-6 resept\u00f6r\u00fc, ligand ba\u011flay\u0131c\u0131 \u03b1-alt birimi (IL-6R\u03b1, CD126) ve sinyal e\u015f resept\u00f6r\u00fc gp130'dan (IL-6R\u03b2, CD130) olu\u015fur. \u0130ki sinyal modu vard\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Klasik sinyalizasyon<\/strong><br>T h\u00fccreleri, B h\u00fccreleri, monositler \u00fczerinde membrana ba\u011fl\u0131 IL-6R\u03b1 \u2192 IL-6\/IL-6R\u03b1\/gp130 kompleksi \u2192 JAK1\/2 \u2192 STAT3, STAT1, MAPK, PI3K\/AKT<\/li>\n\n\n\n<li><strong>Trans sinyalizasyon<\/strong><br>\u00c7\u00f6z\u00fcnebilir IL-6R\u03b1 (sIL-6R) IL-6'y\u0131 ba\u011flar ve membrana ba\u011fl\u0131 IL-6R\u03b1 i\u00e7ermeyen h\u00fccrelerde bile gp130'u aktive eder (\u00f6rn. BBB'nin endotel h\u00fccreleri)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130lgili a\u015fa\u011f\u0131 ak\u0131\u015f etkileri: ROR\u03b3t ifadesi (Th17), Bcl-6 (Tfh ve germinal merkezler), Blimp-1 (plazma h\u00fccreleri), FoxP3'\u00fcn bask\u0131lanmas\u0131 (Treg).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\"><\/span>T-h\u00fccresi resept\u00f6r\u00fc (TCR) ve kostim\u00fclasyon molek\u00fclleri<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TCR\/MHC-II-MOG peptit kompleksi<\/strong><br>MOG-spesifik CD4+ T h\u00fccreleri i\u00e7in merkezi aktivasyon ekseni<\/li>\n\n\n\n<li><strong>CD28\/B7<\/strong><br>T-h\u00fccresi aktivasyonu s\u0131ras\u0131nda kostim\u00fclasyon<\/li>\n\n\n\n<li><strong>CCR6\/CCL20 ekseni<\/strong><br>Th17 h\u00fccreleri \u00fczerindeki CCR6, koroid pleksusta CCL20'yi ba\u011flar \u2192 CNS giri\u015fi<\/li>\n\n\n\n<li><strong>CXCR3\/CXCL10<\/strong><br>Enflamasyon alanlar\u0131nda Th1 h\u00fccrelerinin kemotaksisi<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementrezeptoren\"><\/span>Kompleman resept\u00f6rleri<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C1qR<\/strong><br>Oligodendrosit membranlar\u0131 \u00fczerindeki ba\u011f\u0131\u015f\u0131kl\u0131k komplekslerine C1q ba\u011flanmas\u0131na arac\u0131l\u0131k eder<\/li>\n\n\n\n<li><strong>C3aR <\/strong>ve<strong> C5aR1 (CD88)<\/strong><br>Mikroglia\/makrofajlar \u00fczerindeki anafilatoksin resept\u00f6rleri \u2192 Proinflamatuvar aktivasyon<\/li>\n\n\n\n<li><strong>Oligodendrositler \u00fczerinde kompleman d\u00fczenleyicileri<\/strong><br>CR1 (CD35), MCP (CD46), HRF (CD59) oligodendrositlerde d\u00fc\u015f\u00fck oranda eksprese edilir, bu da onlar\u0131 kompleman hasar\u0131na kar\u015f\u0131 astrositlerden daha duyarl\u0131 hale getirir, \u00f6rne\u011fin<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Histopathologie_und_ZNS-Lasionsmuster\"><\/span>Histopatoloji ve MSS lezyon paterni<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD lezyonlar\u0131 histopatolojik olarak MS ve NMOSD'den temelde farkl\u0131d\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Periven\u00f6z demiyelinizasyon<\/strong><br>Lezyonlar MS'te oldu\u011fu gibi periaksiyel de\u011fil, k\u00fc\u00e7\u00fck damarlar\u0131n etraf\u0131nda konsantrik olarak olu\u015fur (periven\u00f6z patern). MS'in tipik \u201amerkezi damar i\u015fareti\u2018 MRG'de yoktur<\/li>\n\n\n\n<li><strong>CD4+ T-h\u00fccresi infiltrat\u0131<\/strong><br>Bask\u0131n inflamatuar h\u00fccre paterni CD4+ T h\u00fccreleri ve makrofajlard\u0131r, daha az n\u00f6trofil ve neredeyse hi\u00e7 eozinofil gran\u00fclosit yoktur (AQP4+ NMOSD'nin aksine)<\/li>\n\n\n\n<li><strong>Oligodendrosit hasar\u0131<\/strong> (birincil)<br>Astrositlerin \u00f6ncelikli olarak hasar g\u00f6rd\u00fc\u011f\u00fc NMOSD'nin aksine, MOGAD oligodendrosit dejenerasyonu ile karakterizedir<\/li>\n\n\n\n<li><strong>C9neo birikimi<\/strong><br>NMOSD'ye g\u00f6re daha zay\u0131f olsa da lezyonlarda MAC (terminal kompleman kompleksi) saptanmas\u0131<\/li>\n\n\n\n<li><strong>G\u00f6receli akson korunumu<\/strong><br>Akut ataklarda, aksonal hasar genellikle MS'ten daha az \u015fiddetlidir ve bu da genellikle iyi klinik iyile\u015fmeyi a\u00e7\u0131klar<\/li>\n\n\n\n<li><strong>Kortikal lezyonlar<\/strong><br>Leptomeningeal inflamasyon ve kortikal demiyelinizasyon (ADEM varyant\u0131nda yayg\u0131n)<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Manifestationen_und_Phanotypen\"><\/span>Klinik belirtiler ve fenotipler<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD klinik olarak heterojendir. \u00d6nemli fenotipler:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Fenotip<\/strong><\/td><td><strong>Frekans<\/strong><\/td><td><strong>Klinik \u00f6zellikler<\/strong><\/td><td><strong>MRI uzmanl\u0131klar\u0131<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Optik n\u00f6rit (ON)<\/td><td>En yayg\u0131n (yakla\u015f\u0131k 50%)<\/td><td>Genellikle bilateral, g\u00f6rme kayb\u0131, retrobulber, a\u011fr\u0131l\u0131 g\u00f6z hareketleri. g\u00f6z hareketleri<\/td><td>Uzun optik sinir tutulumu, perin\u00f6ral kontrast madde birikimi<\/td><\/tr><tr><td>Transvers miyelit<\/td><td>Yakla\u015f\u0131k. 30%<\/td><td>Longitudinal miyelit (LETM), duyusal\/motor, mesane bozukluklar\u0131<\/td><td>Longitudinal T2 lezyonlar\u0131, H2 sendromu (\u201alentik\u00fcler\u2018)<\/td><\/tr><tr><td>ADEM<\/td><td>\u00c7ocuklarda en s\u0131k g\u00f6r\u00fclen belirtiler<\/td><td>Ensefalopati, polifokal n\u00f6rolojik defisitler a\u00e7\u0131klar<\/td><td>Bilateral, geni\u015f hacimli T2 lezyonlar\u0131, ayr\u0131ca bazal gangliyonlar<\/td><\/tr><tr><td>Beyin sap\u0131 ensefaliti<\/td><td>Yakla\u015f\u0131k. 15%<\/td><td>Diplopi, ataksi, area postrema sendromu (h\u0131\u00e7k\u0131r\u0131k, kusma)<\/td><td>Beyin sap\u0131 \/ serebellar T2 lezyonlar\u0131<\/td><\/tr><tr><td>Kortikal ensefalit<\/td><td>Daha Nadir<\/td><td>Epileptik n\u00f6betler, kafa kar\u0131\u015f\u0131kl\u0131\u011f\u0131<\/td><td>Kortikal FLAIR sinyal de\u011fi\u015fiklikleri<\/td><\/tr><tr><td>CRION<\/td><td>Daha Nadir<\/td><td>Kronik tekrarlayan inflamasyon. Optik n\u00f6ropati<\/td><td>Kal\u0131c\u0131 optik sinir hasar\u0131<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnostik\"><\/span>Te\u015fhis<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Tan\u0131 kriterleri (Banwell ve ark, <em>Lancet N\u00f6roloji<\/em> 2023) gereklidir: <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(1) H\u00fccre bazl\u0131 bir test (CBA) kullan\u0131larak serum veya beyin omurilik s\u0131v\u0131s\u0131nda MOG-IgG tespiti<br>(2) uygun klinik fenotip<br>(3) Alternatif tan\u0131lar\u0131n hari\u00e7 tutulmas\u0131.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>H\u00fccre tabanl\u0131 imm\u00fcnofloresan testi (CBA)<\/strong><br>do\u011fal olarak katlanm\u0131\u015f, membrana ba\u011fl\u0131 MOG ile (insan MOG ile transfekte edilmi\u015f HEK293 h\u00fccreleri); konformasyona ba\u011fl\u0131 epitoplar\u0131 tespit eder<\/li>\n\n\n\n<li><strong>ELISA ve \u00e7izgi\/\u015ferit blotlar<\/strong><br>Do\u011frusal epitoplar tan\u0131nd\u0131\u011f\u0131 i\u00e7in MOGAD i\u00e7in g\u00fcvenilmez<\/li>\n\n\n\n<li><strong>IgG alt s\u0131n\u0131flar\u0131<\/strong><br>\u00d6ncelikle IgG1; bazen IgG2, IgG3, IgG4. Sadece IgG3 pozitifli\u011fi tan\u0131sal bir tuzakt\u0131r (Jarius 2024)<\/li>\n\n\n\n<li><strong>Titre kineti\u011fi<\/strong><br>Kal\u0131c\u0131 olarak y\u00fcksek titreler n\u00fcks riski ile ili\u015fkilidir; monofazik seyirde genellikle azal\u0131r<\/li>\n\n\n\n<li><strong>Lik\u00f6r<\/strong><br>Pleositoz m\u00fcmk\u00fcnd\u00fcr; oligoklonal bantlar nadirdir (&lt;10 %), intratekal IgG sentezi nadirdir<\/li>\n\n\n\n<li><strong>Biyobelirte\u00e7ler<\/strong><br>Hastal\u0131k aktivitesi belirteci olarak sNfL (serum n\u00f6rofilament hafif zincir); astrositik tutulum belirteci olarak sGFAP (glial fibriler asidik protein)<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutische_Strategien\"><\/span>Terap\u00f6tik stratejiler<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Akuttherapie_Schubbehandlung\"><\/span>Akut tedavi (n\u00fcks tedavisi)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD n\u00fcks\u00fcn\u00fcn standart tedavisi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Y\u00fcksek dozda <em>Metilprednizolon<\/em> (HDMP)<\/strong><br>5 g\u00fcn boyunca g\u00fcnde 1000 mg i.v. - birinci basamak<\/li>\n\n\n\n<li><em><strong>Plazmaferez \/ imm\u00fcnoadsorpsiyon<\/strong><\/em><br>Yetersiz HDMP yan\u0131t\u0131 durumunda; MOG-IgG'yi plazmadan uzakla\u015ft\u0131r\u0131r; 5-7 d\u00f6ng\u00fc (retrospektif veriler vakalar\u0131n yakla\u015f\u0131k 50-70%'sinde etkinlik g\u00f6stermektedir)<\/li>\n\n\n\n<li><strong><em>\u0130ntraven\u00f6z imm\u00fcnoglobulinler<\/em> (IVIG)<\/strong><br>5 g\u00fcn boyunca 2 g\/kg; HDMP'ye yan\u0131t yoklu\u011funda ve plazmaferez sonras\u0131 bir se\u00e7enek olarak; muhtemelen FcRn sat\u00fcrasyonu ve Fc\u03b3R rekabeti yoluyla etkili<\/li>\n\n\n\n<li><strong>Kortikosteroidleri azalt\u0131n<\/strong><br>MOGAD'da (s\u0131k steroid ba\u011f\u0131ml\u0131l\u0131\u011f\u0131) \u00f6zellikle \u00f6nemlidir - h\u0131zl\u0131 azalma rebound epizodlar\u0131n\u0131 tetikleyebilir<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prophylaktische_Langzeittherapie\"><\/span>Profilaktik uzun s\u00fcreli tedavi<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">(endikasyon d\u0131\u015f\u0131, ruhsatl\u0131 preparat yok - stat\u00fc 2026)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Uzun s\u00fcreli tedavi endikasyonu bireyseldir - t\u00fcm hastalar\u0131n buna ihtiyac\u0131 yoktur. Fakt\u00f6rler: N\u00fcks oran\u0131, n\u00fckslerin \u015fiddeti, kal\u0131c\u0131 MOG-IgG titreleri, fenotipik risk fakt\u00f6rleri.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Madde<\/strong><\/td><td><strong>Etki mekanizmas\u0131<\/strong><\/td><td><strong>Veri durumu<\/strong><\/td><td><strong>Kan\u0131t d\u00fczeyi<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Azathioprine<\/td><td>P\u00fcrin sentezi blokaj\u0131 (TPMT ba\u011f\u0131ml\u0131); T ve B h\u00fccre proliferasyonunu inhibe eder<\/td><td>Retrospektif \u00e7al\u0131\u015fmalar; devam eden ulusal RK\u00c7 (Fransa, TOMATO \u00e7al\u0131\u015fmas\u0131)<\/td><td>IIb-III (etiket d\u0131\u015f\u0131)<\/td><\/tr><tr><td>Mikofenolat mofetil (MMF)<\/td><td>\u0130nozin monofosfat dehidrojenaz inhibit\u00f6r\u00fc; lenfosit proliferasyonunu inhibe eder<\/td><td>Vaka serileri; muhtemelen etkili, rituksimabdan daha d\u00fc\u015f\u00fck n\u00fcks \u00f6nleme<\/td><td>III (etiket d\u0131\u015f\u0131)<\/td><\/tr><tr><td>Rituximab<\/td><td>Anti-CD20 \u2192 B-h\u00fccre t\u00fckenmesi; MOG-IgG \u00fcretimini engeller<\/td><td>En b\u00fcy\u00fck retrospektif kohort; etkili, herkes i\u00e7in de\u011fil; enfeksiyon riskinde art\u0131\u015f<\/td><td>IIb (etiket d\u0131\u015f\u0131)<\/td><\/tr><tr><td>Tocilizumab<\/td><td>Anti-IL-6R\u03b1 (iv); IL-6 sinyal yolunu bloke eder (JAK\/STAT3); Th17\/plazma h\u00fccrelerini inhibe eder<\/td><td>Pozitif retrospektif veriler; NMOSD i\u00e7in RCT sonu\u00e7lar\u0131 pozitif (TANGO)<\/td><td>IIb (etiket d\u0131\u015f\u0131)<\/td><\/tr><tr><td>IVIG (iv\/derialt\u0131)<\/td><td>Fc resept\u00f6r doygunlu\u011fu; MOG-IgG n\u00f6tralizasyonu; FcRn doygunlu\u011fu<\/td><td>Retrospektif veriler pozitif; do\u011furganl\u0131k, gebelik, enfeksiyon i\u00e7in se\u00e7enek<\/td><td>IIb (etiket d\u0131\u015f\u0131)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Studien_%E2%80%93_2024%E2%80%932026\"><\/span>Klinik \u00e7al\u0131\u015fmalar - 2024-2026<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130lk kez, MOGAD i\u00e7in s\u0131n\u0131f I kan\u0131t sa\u011flamas\u0131 beklenen birka\u00e7 randomize, plasebo kontroll\u00fc faz 3 \u00e7al\u0131\u015fmas\u0131 devam etmektedir:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>\u00c7al\u0131\u015fma<\/strong><\/td><td><strong>Madde<\/strong><\/td><td><strong>Mekanizma<\/strong><\/td><td><strong>Hedef grup<\/strong><\/td><td><strong>Durum<\/strong><\/td><\/tr><\/thead><tbody><tr><td>cosMOG<\/td><td>Rozanolixizumab (UCB7665)<\/td><td>Anti-FcRn IgG4-mAb: IgG geri d\u00f6n\u00fc\u015f\u00fcm\u00fcn\u00fc engeller \u2192 IgG degradasyonunu h\u0131zland\u0131r\u0131r, MOG IgG titresini d\u00fc\u015f\u00fcr\u00fcr ~50 %<\/td><td>Yeti\u015fkinler (\u226518 ya\u015f), n\u00fckseden, \u22651 n\u00fcks\/12 ay<\/td><td>Faz 3, uluslararas\u0131; ilk MOGAD Faz 3 \u00e7al\u0131\u015fmas\u0131<\/td><\/tr><tr><td>METEORO\u0130D<\/td><td>Satralizumab (anti-IL-6R sc.)<\/td><td>Anti-IL-6R (subkutan); JAK\/STAT3'\u00fc inhibe eder \u2192 Th17 farkl\u0131la\u015fmas\u0131, B-h\u00fccresi olgunla\u015fmas\u0131, IgG \u00fcretimi<\/td><td>Yeti\u015fkinler + ergenler (\u226512 ya\u015f); n\u00fcks eden, \u00f6ncesinde \u22651 n\u00fcks olan<\/td><td>A\u015fama 3, uluslararas\u0131, devam ediyor<\/td><\/tr><tr><td>DOMATES<\/td><td>Azathioprine<\/td><td>P\u00fcrin sentezi inhibisyonu; geni\u015f \u00f6l\u00e7\u00fcde imm\u00fcnosupresif<\/td><td>Frans\u0131z \u00e7ok merkezli \u00e7al\u0131\u015fma; MOGAD'l\u0131 yeti\u015fkinler<\/td><td>Ulusal RK\u00c7, faz 3<\/td><\/tr><tr><td>MOGwAI<\/td><td>Belirtilmemi\u015f (G\u00f6zlemsel)<\/td><td>Biyobelirte\u00e7 \u00e7al\u0131\u015fmas\u0131: MOG-IgG titresi, sNfL, sGFAP, sCD83'\u00fcn ilerleme belirte\u00e7leri olarak do\u011frulanmas\u0131<\/td><td>Uluslararas\u0131 kohort \u00e7al\u0131\u015fmas\u0131<\/td><td>Devam ediyor<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neue_und_zukunftige_Therapiekonzepte\"><\/span>Yeni ve gelecekteki terapi konseptleri<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Son y\u0131llardaki molek\u00fcler bulgulara dayanarak, MOGAD i\u00e7in a\u015fa\u011f\u0131daki yakla\u015f\u0131mlar tart\u0131\u015f\u0131lmaktad\u0131r:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BTK-Inhibitoren_Bruton-Tyrosin-Kinase\"><\/span>BTK inhibit\u00f6rleri (Bruton tirozin kinaz)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">BTK, B-h\u00fccresi resept\u00f6r sinyal kaskad\u0131nda (PI3K\/AKT\/MAPK) merkezi bir kinazd\u0131r. <strong><em>Tolebrutinib<\/em><\/strong> ve di\u011fer BTK inhibit\u00f6rleri MS ve NMOSD ara\u015ft\u0131rmalar\u0131ndad\u0131r; MOGAD i\u00e7in klinik \u00e7al\u0131\u015fmalar beklemededir. Oral uygulama bir avantaj olacakt\u0131r. Hem B-h\u00fccresi aktivasyonunun hem de miyeloid h\u00fccrelerin (mikroglia-BTK) inhibisyonu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Toleranzinduktion_MOG-Tolerisierung\"><\/span>Tolerans ind\u00fcksiyonu (MOG tolerans\u0131)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Antijene \u00f6zg\u00fc tolerans ind\u00fcksiyonu (\u00f6rne\u011fin MOG peptidleri veya nanopartik\u00fcl tabanl\u0131 yakla\u015f\u0131mlar yoluyla) umut verici bir kavramd\u0131r. Bu <strong><em>Guthy-Jackson Hay\u0131rseverlik Vakf\u0131<\/em><\/strong> \u0130yile\u015ftirici yakla\u015f\u0131mlara y\u00f6nelik ara\u015ft\u0131rmalar\u0131 te\u015fvik eder. Avantaj\u0131: Global imm\u00fcnosupresyon yok, <strong>MOG otoreaktivitesinin se\u00e7ici olarak ortadan kald\u0131r\u0131lmas\u0131<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementinhibitoren\"><\/span>Kompleman inhibit\u00f6rleri<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Kompleman aktivasyonu (C3a, C5a, MAC) MOGAD lezyonlar\u0131nda tespit edilebildi\u011finden <strong><em>Eculizumab<\/em> (Anti-C5)<\/strong> veya bir C3 inhibit\u00f6r\u00fc teorik olarak etkilidir. Ancak MAC kompleksi (C5b-9) MOGAD'da NMOSD'ye g\u00f6re \u00e7ok daha az oranda olu\u015ftu\u011fu i\u00e7in (burada <em>Eculizumab<\/em> yetkilendirilmi\u015ftir), klinik \u00f6nemi belirsizdir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Anti-Neonatal-Fc-Rezeptor-Strategien\"><\/span>Anti-neonatal Fc resept\u00f6r stratejileri<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ayr\u0131ca <em>Rozanolixizumab<\/em> ayr\u0131ca <strong><em>Efgartigimod<\/em><\/strong> (FcRn'yi rekabet\u00e7i bir \u015fekilde bloke eden bir IgG-Fc fragman\u0131) di\u011fer IgG arac\u0131l\u0131 hastal\u0131klar i\u00e7in. FcRn blokaj\u0131n\u0131n patomekanizmas\u0131 do\u011frudan MOG-IgG seviyesini d\u00fc\u015f\u00fcrd\u00fc\u011f\u00fcnden, bu \u00f6zellikle hedef odakl\u0131 bir yakla\u015f\u0131md\u0131r.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\"><\/span>Otolog hematopoietik k\u00f6k h\u00fccre transplantasyonu (aHSCT)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">\u015eiddetli, refrakter seyirler i\u00e7in aHSCT potansiyel olarak iyile\u015ftirici bir konsepttir: derin imm\u00fcnoablasyon ve imm\u00fcn sistemin yeniden yap\u0131land\u0131r\u0131lmas\u0131 otoreaktif T ve B h\u00fccre klonlar\u0131n\u0131 ortadan kald\u0131rabilir. MOGAD i\u00e7in mevcut veriler \u00e7ok s\u0131n\u0131rl\u0131d\u0131r; yaln\u0131zca uzmanla\u015fm\u0131\u015f merkezlerde kullan\u0131l\u0131r.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biomarker_und_Verlaufsmonitoring\"><\/span>Biyobelirte\u00e7ler ve takip izleme<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Biyobelirte\u00e7 temelli tedavi kararlar\u0131 g\u00fcncel ara\u015ft\u0131rmalar\u0131n hedefidir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MOG-IgG titresi (serum)<\/strong><br>Persistans relaps riski ile ili\u015fkilidir; monofazik seyirde s\u0131kl\u0131kla titrede spontan d\u00fc\u015f\u00fc\u015f; tedavi karar\u0131 ortak belirleyicidir<\/li>\n\n\n\n<li><strong>Serum N\u00f6rofilament I\u015f\u0131\u011f\u0131 (sNfL)<\/strong><br>Aksonal hasar belirteci; n\u00fcks s\u0131ras\u0131nda y\u00fckselir; tedaviye yan\u0131t belirteci olarak normalle\u015fme<\/li>\n\n\n\n<li><strong>Serum GFAP (sGFAP)<\/strong><br>Astrositik aktivasyon; MOGAD'da NMOSD'ye g\u00f6re daha d\u00fc\u015f\u00fckt\u00fcr; tamamlay\u0131c\u0131 bilgi sa\u011flayabilir<\/li>\n\n\n\n<li><strong>sCD83<\/strong><br>Yeni aday biyobelirte\u00e7 (do\u011frulama a\u015famas\u0131nda); muhtemelen dendritik h\u00fccre aktivasyonu ve ba\u011f\u0131\u015f\u0131kl\u0131k aktivitesi i\u00e7in belirte\u00e7<\/li>\n\n\n\n<li><strong>Beyin omurilik s\u0131v\u0131s\u0131 h\u00fccre say\u0131m\u0131 ve proteini<\/strong><br>\u0130tme ataklar\u0131 s\u0131ras\u0131nda pleositoz; tedaviden sonra normalle\u015fme<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prognose_und_Besonderheiten\"><\/span>Tahmin ve \u00f6zel \u00f6zellikler<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">AQP4+ NMOSD ile kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, MOGAD bir <strong>Daha olumlu tahminler<\/strong>, \u00f6zellikle ON sonras\u0131 daha iyi g\u00f6rsel iyile\u015fme. Bununla birlikte, a\u015fa\u011f\u0131daki hususlar \u00f6nemlidir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monofazik ilerleme<\/strong><br>Hastalar\u0131n yakla\u015f\u0131k 50%'si; genellikle titrede kendili\u011finden d\u00fc\u015f\u00fc\u015f; uzun s\u00fcreli tedavi gerekmeyebilir<\/li>\n\n\n\n<li><strong>\u0130tme \u015feklinde ilerleme<\/strong><br>Yakla\u015f\u0131k 50%; daha y\u00fcksek titre devam eder; k\u00fcm\u00fclatif sakatl\u0131k olu\u015fumu m\u00fcmk\u00fcnd\u00fcr, ancak NMOSD'den daha yava\u015ft\u0131r<\/li>\n\n\n\n<li><strong>A\u015famal\u0131 kurs yok<\/strong><br>MS'in aksine, n\u00fcksler olmaks\u0131z\u0131n kademeli bir ilerleme tan\u0131mlanmam\u0131\u015ft\u0131r<\/li>\n\n\n\n<li><strong>Steroid duyarl\u0131l\u0131\u011f\u0131 ve steroid ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong><br>Bununla birlikte, bir\u00e7ok hasta kortikosteroidlere \u00e7ok iyi yan\u0131t verir: h\u0131zl\u0131 azaltma genellikle n\u00fcksleri tetikler<\/li>\n\n\n\n<li><strong>\u00d6zel pediyatrik \u00f6zellik<\/strong><br>ADEM \u00e7ocuklarda (&lt;10 ya\u015f) en s\u0131k g\u00f6r\u00fclen ba\u015flang\u0131\u00e7 belirtisidir; prognoz genellikle iyidir, ancak n\u00fcks riskine dikkat edilmelidir<\/li>\n\n\n\n<li><strong>Hamilelik: zay\u0131f veri<\/strong><br>Hamilelik s\u0131ras\u0131nda genel olarak artm\u0131\u015f n\u00fcks riski yoktur, ancak do\u011fum sonras\u0131 bir risk fakt\u00f6r\u00fc olabilir (MS'e benzer)<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zusammenfassung_und_Ausblick\"><\/span>\u00d6zet ve genel g\u00f6r\u00fcn\u00fcm<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD, a\u015fa\u011f\u0131daki temel \u00f6zelliklerle karakterize edilen, MSS'nin ba\u011f\u0131ms\u0131z, antikor arac\u0131l\u0131 otoimm\u00fcn bir hastal\u0131\u011f\u0131d\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Oligodendrositlerin ve miyelin k\u0131l\u0131flar\u0131n\u0131n d\u0131\u015f\u0131nda bulunan MOG proteini hedef antijendir<\/li>\n\n\n\n<li>Patojenik MOG-IgG1 otoantikorlar\u0131 miyeline iki paralel efekt\u00f6r yolu ile zarar verir: kompleman aktivasyonu (CDC, yakla\u015f\u0131k 50%) ve Fc\u03b3R ba\u011flanmas\u0131 (ADCC\/ADCP, yakla\u015f\u0131k 50%)<\/li>\n\n\n\n<li>Buna ek olarak, antikorlar Fc\u03b3R mekanizmalar\u0131 arac\u0131l\u0131\u011f\u0131yla T-h\u00fccresi aktivasyonunu g\u00fc\u00e7lendirir<\/li>\n\n\n\n<li>IL-6\/JAK\/STAT3 sinyal yolu Th17 farkl\u0131la\u015fmas\u0131n\u0131 ve plazma h\u00fccresi olgunla\u015fmas\u0131n\u0131 destekler ve \u00f6nemli bir terap\u00f6tik hedeftir<\/li>\n\n\n\n<li>\u015eu anda onaylanm\u0131\u015f bir tedavi yoktur (\u015eubat 2026 itibariyle); ilk faz 3 RK\u00c7'ler devam etmektedir (rozanolixizumab ile cosMOG, satralizumab ile METEOROID)<\/li>\n\n\n\n<li>Tedavi, riske uyarlanm\u0131\u015f, biyobelirte\u00e7 tabanl\u0131 stratejiler y\u00f6n\u00fcnde ilerliyor<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Son y\u0131llardaki en \u00f6nemli ara\u015ft\u0131rma ilerlemesi, a\u015fa\u011f\u0131daki gibi ara\u015ft\u0131rma gruplar\u0131 taraf\u0131ndan efekt\u00f6r mekanizmalar\u0131n\u0131n (kompleman ve FcR yolu) kesin olarak \u00e7\u00f6z\u00fclmesi olmu\u015ftur <strong>Meinl, Mader, Kawakami (LMU M\u00fcnih)<\/strong>, Bu da tedavi geli\u015fimi i\u00e7in do\u011frudan etkilere sahiptir: Optimal bir terap\u00f6tik yakla\u015f\u0131m IgG \u00fcretiminin (anti-CD20, FcRn inhibit\u00f6rleri) yan\u0131 s\u0131ra efekt\u00f6r mekanizmalar\u0131 (kompleman, Fc\u03b3R) ve Th17\/IL-6 eksenini de ele almal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tolerans ind\u00fcksiyon stratejileri ve BTK inhibit\u00f6rleri, \u00f6n\u00fcm\u00fczdeki y\u0131llarda klinik olarak denenmesi muhtemel, gelece\u011fe y\u00f6nelik, mekanistik temelli terap\u00f6tik ilkeleri temsil etmektedir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\"><\/span>U\u00e7ucu ya\u011flar - sinyal yollar\u0131na g\u00f6re s\u0131ralanm\u0131\u015f aktif bile\u015fenler<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Aktif maddeler, MOGAD patofizyolojisindeki sald\u0131r\u0131 noktalar\u0131na g\u00f6re k\u00fcmelenebilir. Bu \u00e7ok \u00f6nemlidir \u00e7\u00fcnk\u00fc MOGAD'\u0131n \u00fc\u00e7 ana ekseni vard\u0131r: <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong><\/li>\n\n\n\n<li><strong>Kompleman sistemi\/oligodendrosit korumas\u0131<\/strong><\/li>\n\n\n\n<li><strong>Remiyelinizasyon\/OPC farkl\u0131la\u015fmas\u0131<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\"><\/span>Frankincense (Boswellia serrata) - AKBA ve incensol asetat<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">BCP'ye g\u00f6re bu, MOGAD i\u00e7in bilimsel olarak kan\u0131tlanm\u0131\u015f en iyi adayd\u0131r ve etki yelpazesi a\u00e7\u0131s\u0131ndan istisnai bir durumdur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AKBA (3-O-asetil-11-keto-\u03b2-boswellic asit)<\/strong> ana aktif prensiptir. AKBA, anti-enfeksiy\u00f6z, anti-t\u00fcm\u00f6r ve antioksidan etkilerin yan\u0131 s\u0131ra kan\u0131tlanm\u0131\u015f n\u00f6roprotektif etkiler de dahil olmak \u00fczere bir\u00e7ok fizyolojik etkiye sahiptir. Sinir onar\u0131m\u0131n\u0131 ve rejenerasyonunu destekler, iskemik beyin hasar\u0131na kar\u015f\u0131 korur, n\u00f6roinflamasyonu inhibe eder ve haf\u0131za eksikliklerini iyile\u015ftirir. <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">Avrupa N\u00f6roloji Akademisi<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AKBA STAT3'\u00fc inhibe eder<\/strong> STAT3, MOGAD'da Th17 farkl\u0131la\u015fmas\u0131n\u0131 ve plazma h\u00fccresi olgunla\u015fmas\u0131n\u0131 y\u00f6nlendiren IL-6\/JAK sinyal yolunun ana efekt\u00f6r transkripsiyon fakt\u00f6r\u00fc oldu\u011fu i\u00e7in doza ba\u011fl\u0131, anahtar bir mekanizmad\u0131r. Buna ek olarak, Nrf2\/HO-1 sinyal yolunun AKBA taraf\u0131ndan etkinle\u015ftirilmesi oksidatif hasar\u0131 azaltmak, demiyelinizasyonu \u00f6nlemek ve remiyelinizasyonu te\u015fvik etmek i\u00e7in bir y\u00f6n sa\u011flar. <a href=\"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.nanolett.9b02220\" target=\"_blank\" rel=\"noreferrer noopener\">ACS Yay\u0131nlar\u0131<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AKBA, 5-LOX ve 15-LOX'un allosterik mod\u00fclasyonu yoluyla l\u00f6kotrien olu\u015fumunu engelleyen, ancak ayn\u0131 zamanda SPM (\u00d6zel Pro-Resolving Mediators) \u00fcretimini uyaran molek\u00fcler bir anahtar g\u00f6revi g\u00f6r\u00fcr. Bu, ba\u011f\u0131\u015f\u0131kl\u0131k tepkisini aktif olarak \u015fu y\u00f6ne kayd\u0131r\u0131r <strong>Enflamasyonun \u00e7\u00f6z\u00fclmesi<\/strong>, sadece s\u00f6n\u00fcmleme de\u011fil. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39133885\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u0130nkensol asetat<\/strong> (buhur u\u00e7ucu ya\u011f\u0131n\u0131n u\u00e7ucu bile\u015feni, BHS olur) n\u00f6ronlardaki TRPV3 kanallar\u0131n\u0131 ve PPAR-\u03b3'y\u0131 aktive eder - Buhur bile\u015fenleri, ind\u00fcklenmi\u015f inflamasyondan sonra beyindeki IL-6, TNF-\u03b1 ve GFAP'\u0131 (astrosit aktivasyonu belirteci) \u00f6nemli \u00f6l\u00e7\u00fcde azaltabilir. <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200293\" target=\"_blank\" rel=\"noreferrer noopener\">N\u00f6roloji<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00d6nemli kalite notu:<\/strong> Boswellia \u00fcr\u00fcnleri aras\u0131nda \u00f6nemli kalite farkl\u0131l\u0131klar\u0131 vard\u0131r, baz\u0131 \u00fcr\u00fcnler (\u00f6rne\u011fin H15 Ayurmedica\u00ae) analizlerde sadece eser miktarda karakteristik boswellic asit (0,31 mg AKBA) i\u00e7ermi\u015ftir. Buna kar\u015f\u0131l\u0131k, BOSWELLIASAN\u00ae (7.51 mg) ve Sallaki\u00ae Tablets (7.88 mg) gibi \u00fcr\u00fcnler \u00f6nemli miktarda AKBA ve buna ba\u011fl\u0131 olarak g\u00fc\u00e7l\u00fc farmakolojik etkiler g\u00f6stermi\u015ftir. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34358086\/\" target=\"_blank\" rel=\"noreferrer noopener\">Enflamasyonu Mod\u00fcle Eden Buhur Bazl\u0131 Remedilerin Boswellic Asit \u0130\u00e7eriklerinin ve \u0130lgili Farmakolojik Aktivitelerinin Analizi<\/a> ve <a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2025.1530977\/full\" target=\"_blank\" rel=\"noreferrer noopener\">S\u0131n\u0131rlar<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">doTERRA \u00fcr\u00fcn\u00fc <strong><a href=\"https:\/\/media.doterra.com\/us\/en\/pips\/frankincense-boswellic-acid-complex.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Frankincense Boswellic Asit Kompleksi<\/a><\/strong> 37,5 mg AKBA* i\u00e7erir<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutisch_relevante_AKBA-Zieldosen\"><\/span>Terap\u00f6tik olarak ilgili AKBA hedef dozlar\u0131<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik ve klinik \u00f6ncesi ara\u015ft\u0131rmalardan a\u015fa\u011f\u0131daki tablo ortaya \u00e7\u0131kmaktad\u0131r:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Uygulama hedefi<\/th><th>AKBA g\u00fcnl\u00fck doz<\/th><th>Kaynak<\/th><\/tr><\/thead><tbody><tr><td>Anti-enflamatuar (genel)<\/td><td>100-200 mg<\/td><td>\u0130nsan \u00e7al\u0131\u015fmalar\u0131 eklem\/ba\u011f\u0131rsak<\/td><\/tr><tr><td>NF-\u03baB \/ STAT3 inhibisyonu (n\u00f6roinflamasyon)<\/td><td>200-400 mg<\/td><td>Hayvan modelleri, h\u00fccre k\u00fclt\u00fcr\u00fc<\/td><\/tr><tr><td>Optimum MSS etkisi (bariyer ge\u00e7i\u015fi)<\/td><td>200-300 mg<\/td><td>Deneysel veriler<\/td><\/tr><tr><td>\u0130yi tolere edilen en y\u00fcksek g\u00fcnl\u00fck doz<\/td><td>400-600 mg<\/td><td>Tolerans \u00e7al\u0131\u015fmalar\u0131<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Umrechnung_auf_375_mg_AKBA_jeKapsel\"><\/span>Kaps\u00fcl ba\u015f\u0131na 37,5 mg AKBA'ya d\u00f6n\u00fc\u015ft\u00fcrme<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Hedef AKBA g\u00fcnl\u00fck dozu<\/th><th>Birim\/g\u00fcn<\/th><th>Pratik \u015fema<\/th><\/tr><\/thead><tbody><tr><td>150 mg<\/td><td>4 adet<\/td><td>2 \u00d7 sabah + 2 \u00d7 ak\u015fam<\/td><\/tr><tr><td>200 mg<\/td><td><strong>5-6 birim<\/strong><\/td><td>3 \u00d7 sabah + 2-3 \u00d7 ak\u015fam<\/td><\/tr><tr><td>300 mg<\/td><td>8 adet<\/td><td>4 \u00d7 sabah + 4 \u00d7 ak\u015fam<\/td><\/tr><tr><td>400 mg<\/td><td>10-11 adet<\/td><td>G\u00fcnde 3 \u00d7 3-4 \u00fcnite<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tavsiye edilen giri\u015f:<\/strong> <strong>G\u00fcnde 4 \u00fcnite (= 150 mg AKBA)<\/strong>, 2 hediyeye b\u00f6l\u00fcnm\u00fc\u015ft\u00fcr.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">2 hafta sonra - iyi tolere edilirse - 6 \u00fcniteye (= 225 mg) y\u00fckseltin.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_Einnahmehinweise\"><\/span>\u00d6nemli al\u0131m talimatlar\u0131<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ya\u011f \u00e7ok \u00f6nemlidir:<\/strong> AKBA y\u00fcksek oranda lipofiliktir. <strong>Biyoyararlan\u0131m 2-3 kat artar<\/strong>, Ya\u011fl\u0131 bir yemekle birlikte al\u0131nd\u0131\u011f\u0131nda. Zeytinya\u011f\u0131, avokado veya bir ana yemek idealdir. A\u00e7 karn\u0131na al\u0131nmas\u0131 emilimi b\u00fcy\u00fck \u00f6l\u00e7\u00fcde azalt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Zamanlama:<\/strong> AKBA'n\u0131n yar\u0131 \u00f6mr\u00fc yakla\u015f\u0131k 6 saattir, bu nedenle <strong>G\u00fcnde 2-3 doz<\/strong> Bu, e\u015fit bir etkinlik seviyesini korumak i\u00e7in tek bir dozdan daha mant\u0131kl\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>BCP ile kombinasyon:<\/strong> AKBA (STAT3\/NF-\u03baB ekseni) ve BCP (CB2\/Th17 ekseni) MOGAD'daki farkl\u0131 sinyal yollar\u0131na hitap eder ve sinerjik olarak etki eder. Herhangi bir farmakolojik etkile\u015fim bilinmemektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gastrik tolerans:<\/strong> Boswellia genellikle \u00e7ok iyi tolere edilir. Y\u00fcksek dozlarda nadiren hafif mide tahri\u015fi meydana gelir. Bu nedenle, her zaman bir yemekle birlikte al\u0131n veya gerekirse dozu ge\u00e7ici olarak azalt\u0131n.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_oral\"><\/span>Karabiber (oral)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Karabiber ya\u011f\u0131ndaki ana aktif bile\u015fen \u03b2-karyofilen (BCP) (<em>Piper nigrum<\/em>) inflamatuar sitokinler IL-6, TNF-\u03b1, IL-17, IFN-\u03b3 ve Th17 (ROR-\u03b3t) ve Th1 (T-bet) transkripsiyon fakt\u00f6rlerinde azalmaya ve anti-inflamatuar sitokinler TGF-\u03b21, IL-10, IL-4 ve Th2 (GATA3) ve Treg (Foxp3) transkripsiyon fakt\u00f6rlerinde \u00f6nemli bir art\u0131\u015fa neden olur. Bu etkiler kesinlikle CB2 resept\u00f6r aktivasyonu ile ba\u011flant\u0131l\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CB2 resept\u00f6rleri ve remiyelinizasyon mekanik olarak do\u011frudan ba\u011flant\u0131l\u0131d\u0131r: CB2 agonizmi OPC'lerin olgunla\u015fmas\u0131n\u0131 te\u015fvik eder - yeni nesil bir CB2 agonisti (Yhhu4952) miyelin temel proteininin (MBP) ekspresyonunu ve korpus kallozumdaki olgun oligodendrositlerin oran\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131rm\u0131\u015ft\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Karabiber i\u00e7in dozaj: 20 ... 200 mg\/g\u00fcn - 20 tr.\/g\u00fcn'e kar\u015f\u0131l\u0131k gelir - bu nedenle en iyisi her 8 saatte bir 7 trp. (daha y\u00fcksek plazma seviyeleri i\u00e7in tercihen her 6 saatte bir 5 trp.) kaps\u00fcl i\u00e7inde ta\u015f\u0131y\u0131c\u0131 ya\u011f i\u00e7inde almakt\u0131r. Y\u00fcksek ya\u011fl\u0131 yiyecek\/i\u00e7eceklerle birlikte lipofilik olarak.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_Inhalation\"><\/span>Karabiber (inhalasyon)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Dozaj: G\u00fcn boyunca her 4 saatte bir 3 trp. \u0131s\u0131t\u0131lm\u0131\u015f dif\u00fcz\u00f6r\u00fcn Liqui-Pad'ine 20 dakika boyunca soluyun (yar\u0131lanma \u00f6mr\u00fc 2-4 saattir) ve her derin nefesten sonra nefesinizi yakla\u015f\u0131k 5-8 saniye tutun, dif\u00fcz\u00f6r\u00fc gece odada \u00e7al\u0131\u015f\u0131r durumda b\u0131rak\u0131n, do\u011frudan solumay\u0131n.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Karabiber uyar\u0131c\u0131 bir etkiye sahip olabilir ve uykuyu bozabilir. Bu durumda, geceleri yaymay\u0131n.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Solunum yolu tahri\u015f olursa (kuruluk) veya ba\u015f a\u011fr\u0131s\u0131 geli\u015firse: Dozu azalt\u0131n veya aral\u0131klar\u0131 art\u0131r\u0131n.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\"><\/span>Copaiba ya\u011f\u0131 (oral) - SADECE doTERRA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">52,6 % BCP - 14,7 mg BCP\/damlaya kar\u015f\u0131l\u0131k gelir - BCP lipofilik oldu\u011fundan, her zaman y\u00fcksek ya\u011fl\u0131 yiyecek\/i\u00e7ecekle birlikte al\u0131n!<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Klinik g\u00fcvenlik \u00e7al\u0131\u015fmalar\u0131na g\u00f6re, bu durum v\u00fccut a\u011f\u0131rl\u0131\u011f\u0131na ba\u011fl\u0131 olarak a\u015fa\u011f\u0131daki dozaj \u00f6nerisiyle sonu\u00e7lanmaktad\u0131r:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\"><\/span>MOGAD'a \u00f6zg\u00fc dozaj tablosu (doTERRA Copaiba 52.5 % BCP)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>V\u00fccut a\u011f\u0131rl\u0131\u011f\u0131<\/th><th><strong>Koruma<\/strong> (0,4 mg\/kg)<\/th><th><strong>Aktif itme<\/strong> (1.0 mg\/kg)<\/th><th><strong>Yo\u011fun terapi<\/strong> (1,5 mg\/kg)<\/th><\/tr><\/thead><tbody><tr><td><strong>50 kg<\/strong><\/td><td>20 mg = <strong>1-2 damla<\/strong><\/td><td>50 mg = <strong>3-4 damla<\/strong><\/td><td>75 mg = <strong>5 damla<\/strong><\/td><\/tr><tr><td><strong>60 kg<\/strong><\/td><td>24 mg = <strong>2 damla<\/strong><\/td><td>60 mg = <strong>4 damla<\/strong><\/td><td>90 mg = <strong>6 damla<\/strong><\/td><\/tr><tr><td><strong>70 kg<\/strong><\/td><td>28 mg = <strong>2 damla<\/strong><\/td><td>70 mg = <strong>5 damla<\/strong><\/td><td>105 mg = <strong>7 damla<\/strong><\/td><\/tr><tr><td><strong>80 kg<\/strong><\/td><td>32 mg = <strong>2 damla<\/strong><\/td><td>80 mg = <strong>5-6 damla<\/strong><\/td><td>120 mg = <strong>8 damla<\/strong><\/td><\/tr><tr><td><strong>90 kg<\/strong><\/td><td>36 mg = <strong>2-3 damla<\/strong><\/td><td>90 mg = <strong>6 damla<\/strong><\/td><td>135 mg = <strong>9 damla<\/strong><\/td><\/tr><tr><td><strong>100 kg<\/strong><\/td><td>40 mg = <strong>3 damla<\/strong><\/td><td>100 mg = <strong>7 damla<\/strong><\/td><td>150 mg = <strong>10 damla<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-Phasen-adaptierte_Dosierung\"><\/span>MOGAD faza uyarlanm\u0131\u015f dozajlama<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\"><\/span><strong>A\u015fama 1: Akut alevlenme (ilk 2-4 hafta)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hedef:<\/strong> Agresif Th17 bask\u0131lanmas\u0131, IL-6 azalmas\u0131<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dozaj:<\/strong> G\u00fcnl\u00fck 1.0-1.5 mg\/kg<\/li>\n\n\n\n<li><strong>B\u00f6l\u00fcm:<\/strong> G\u00fcnde 3\u00d7 (s\u00fcrekli CB2 resept\u00f6r aktivasyonu i\u00e7in optimal)<\/li>\n\n\n\n<li><strong>\u00d6rnek 70 kg:<\/strong> G\u00fcnde 5-7 damla, 2+2+3 damla olarak da\u011f\u0131t\u0131l\u0131r<\/li>\n\n\n\n<li><strong>Kombinasyon:<\/strong> AKBA (STAT3 inhibisyonu i\u00e7in 200-300 mg\/g\u00fcn) + y\u00fcksek doz kortizon (standart) ile<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_Schubremission_Erhaltung_langfristig\"><\/span><strong>A\u015fama 2: n\u00fcks remisyonu \/ idame (uzun s\u00fcreli)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hedef:<\/strong> N\u00fcks \u00f6nleme, s\u00fcrekli anti-enflamatuar ton<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dozaj:<\/strong> G\u00fcnl\u00fck 0,4-0,7 mg\/kg<\/li>\n\n\n\n<li><strong>B\u00f6l\u00fcm:<\/strong> G\u00fcnde 2 kat<\/li>\n\n\n\n<li><strong>\u00d6rnek 70 kg:<\/strong> G\u00fcnde 2-3 damla, 1+2 veya 2+2 olarak da\u011f\u0131t\u0131l\u0131r<\/li>\n\n\n\n<li><strong>Kombinasyon:<\/strong> AKBA ile (150 mg\/g\u00fcn) iste\u011fe ba\u011fl\u0131<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_Monophasischer_Verlauf_Titer_fallend\"><\/span><strong>A\u015fama 3: Monofazik seyir (d\u00fc\u015fen titre)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hedef:<\/strong> N\u00f6roproteksiyon, remiyelinizasyon<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dozaj:<\/strong> G\u00fcnl\u00fck 0,2-0,4 mg\/kg<\/li>\n\n\n\n<li><strong>B\u00f6l\u00fcm:<\/strong> G\u00fcnde 1-2\u00d7<\/li>\n\n\n\n<li><strong>\u00d6rnek 70 kg:<\/strong> G\u00fcnde 1-2 damla<\/li>\n\n\n\n<li><strong>Dengeleme m\u00fcmk\u00fcn<\/strong> 6-12 ayl\u0131k stabil seronegatiflikten sonra<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen\"><\/span>Kaynaklar<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toksikoloji (700 mg\/kg NOAEL)<\/strong><br><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/<\/a><\/li>\n\n\n\n<li><strong>EAE modeli (2,5-5 mg\/kg etkili)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/<\/a><\/li>\n\n\n\n<li><strong>\u0130nsan \u00e7al\u0131\u015fmas\u0131 (100 mg g\u00fcvenli)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/<\/a><\/li>\n\n\n\n<li><strong>Klinik \u00e7al\u0131\u015fma (126 mg\/g\u00fcn etkili)<\/strong><br><a href=\"https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/\" target=\"_blank\" rel=\"noopener\">https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_Inhalation\"><\/span>Copaiba ya\u011f\u0131 (inhalasyon)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Maksimum 38% BCP i\u00e7eren karabibere ek olarak, 87% BCP'ye kadar olan copaiba ya\u011f\u0131 \u00e7ok daha g\u00fc\u00e7l\u00fcd\u00fcr ve bu nedenle inhalasyon i\u00e7in en iyi se\u00e7imdir.<br>Dif\u00fcz\u00f6rler genellikle so\u011fuk ultrasonik (US) atomizasyon ile \u00e7al\u0131\u015f\u0131r. Ancak BCP sadece 130 \u00b0C civar\u0131nda buharla\u015f\u0131r ve 180 \u00b0C'nin \u00fczerindeki s\u0131cakl\u0131klarda yanar. Bu nedenle \u0131s\u0131t\u0131labilir, s\u0131cakl\u0131k kontroll\u00fc dif\u00fcz\u00f6rler kullan\u0131lmal\u0131d\u0131r (\u00f6rn. <a href=\"https:\/\/storz-bickel.com\" target=\"_blank\" rel=\"noreferrer noopener\">Volcano Classic, Volcano Hybrid veya Mighty+<\/a>) yakla\u015f\u0131k 270 - 415 Euro fiyat aral\u0131\u011f\u0131nda ve s\u0131cakl\u0131k m\u00fcmk\u00fcn oldu\u011funca hassas bir \u015fekilde (IR termometre ile kontrol edin) 160 \u00b0C'ye ayarlanmal\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">69 % BCP i\u00e7erikli Copaiba ya\u011f\u0131 (doTERRA) i\u00e7in \u00f6nerilen dozaj - 1 damla 18,6 mg BCP i\u00e7erir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BCP'nin yar\u0131lanma \u00f6mr\u00fc 2-4 saattir. M\u00fcmk\u00fcn oldu\u011funca sabit bir aktif bile\u015fen seviyesi elde etmek i\u00e7in, yukar\u0131da a\u00e7\u0131kland\u0131\u011f\u0131 gibi her 4 saatte bir 4 damla (yakla\u015f\u0131k 200 mg BCP'ye e\u015fde\u011fer) ile inhalasyon yap\u0131lmal\u0131d\u0131r. Bir dif\u00fcz\u00f6r gece boyunca yata\u011f\u0131n yan\u0131nda \u00e7al\u0131\u015f\u0131r durumda b\u0131rak\u0131labilir.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zieldosen_und_benotigte_Tropfenzahl\"><\/span>Hedef dozlar ve gerekli damla say\u0131s\u0131<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Hedef BCP dozu<\/th><th>Copaiba ya\u011f\u0131 damlalar\u0131<\/th><th>Toplam ya\u011f (mg)<\/th><\/tr><\/thead><tbody><tr><td>20 mg BCP (ba\u015flang\u0131\u00e7 dozu)<\/td><td><strong>~1 damla<\/strong><\/td><td>~29 mg<\/td><\/tr><tr><td>50 mg BCP<\/td><td><strong>~3 damla<\/strong><\/td><td>~72 mg<\/td><\/tr><tr><td>100 mg BCP (terap\u00f6tik)<\/td><td><strong>~5-6 damla<\/strong><\/td><td>~145 mg<\/td><\/tr><tr><td>120 mg BCP (g\u00fcnl\u00fck \u00fcst doz)<\/td><td><strong>~6-7 damla<\/strong><\/td><td>~174 mg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Hedefe y\u00f6nelik inhale BCP<\/th><th>S\u0131v\u0131 ped \u00fczerindeki ya\u011f miktar\u0131<\/th><th>Damlalar<\/th><\/tr><\/thead><tbody><tr><td>\u0130nhale ~20 mg BCP<\/td><td>~40 mg ya\u011f (~78 mg\/0,69)<\/td><td><strong>2-3 damla<\/strong><\/td><\/tr><tr><td>\u0130nhale ~50 mg BCP<\/td><td>~100 mg ya\u011f<\/td><td><strong>4-5 damla<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Synergistische_MOGAD-Strategie_Multi-Target\"><\/span>Sinerjik MOGAD stratejisi (\u00e7oklu hedef)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD \u00fc\u00e7 patomekanizmaya sahip oldu\u011fundan, bu kan\u0131ta dayal\u0131 kombinasyon ortaya \u00e7\u0131kmaktad\u0131r:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aktif bile\u015fen<\/th><th>Doz<\/th><th>Sinyal yolu<\/th><th>MOGAD alaka d\u00fczeyi<\/th><\/tr><\/thead><tbody><tr><td><strong>BCP (oral)<\/strong><\/td><td>0,4-1,5 mg\/kg<\/td><td>CB2 \u2192 Th17\u2193, IL-6\u2193, Nrf2\/HO-1\u2191<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>AKBA (oral)<\/strong><\/td><td>200-400 mg\/g\u00fcn<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>BCP (inhale, 160 \u00b0C)<\/strong><\/td><td>2-3 damla, 2\u00d7\/g\u00fcn<\/td><td>Limbik, h\u0131zl\u0131 MSS penetrasyonu<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>Buhur ya\u011f\u0131 (inhale)<\/strong><\/td><td>3-4 damla, 2\u00d7\/g\u00fcn<\/td><td>\u0130nensol asetat \u2192 TRPV3, PPAR-\u03b3<\/td><td>\u2605\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Bu d\u00f6rt s\u00fctunlu strateji \u015funlar\u0131 ele almaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong> (BCP oral + AKBA)<\/li>\n\n\n\n<li><strong>STAT3<\/strong> (AKBA)<\/li>\n\n\n\n<li><strong>Oligodendrosit korumas\u0131<\/strong> (BCP Nrf2 aktivasyonu)<\/li>\n\n\n\n<li><strong>Limbik mod\u00fclasyon<\/strong> (inhalasyon)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_MOGAD-spezifische_Hinweise\"><\/span>MOGAD'a \u00f6zg\u00fc \u00f6nemli bilgiler<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Monoterapi yok<\/strong> - BCP\/AKBA \u015funlard\u0131r <strong>Geleneksel tedaviye eklentiler<\/strong><br>(kortizon akut, gerekirse rituximab\/MMF\/IVIG profilaktik) - asla ikame olarak de\u011fil<\/li>\n\n\n\n<li><strong>Biyomarker izleme:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Her 3-6 ayda bir MOG-IgG titresi<\/li>\n\n\n\n<li>bir aktivite belirteci olarak sNfL (N\u00f6rofilament I\u015f\u0131\u011f\u0131)<\/li>\n\n\n\n<li>Titreler kal\u0131c\u0131 olarak d\u00fc\u015ferse dozu azaltmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>\u0130tme teti\u011fini g\u00f6zlemleyin<\/strong> - Enfeksiyonlar ana tetikleyicidir<br>Enfeksiyon durumunda, gerekirse doz <strong>ge\u00e7ici olarak 1,5 mg\/kg'a y\u00fckseltilir<\/strong> (\u00f6nleyici)<\/li>\n\n\n\n<li><strong>Copaiba i\u00e7in karaci\u011fer de\u011ferleri<\/strong> - E\u011fer &gt;3 ay boyunca &gt;1 mg\/kg ise<br>ALT\/AST'yi her 3 ayda bir kontrol edin<\/li>\n\n\n\n<li><strong>Karabiber alternatifi<\/strong> - Copaiba endi\u015feleri i\u00e7in: Karabiber ya\u011f\u0131 (25-38 % BCP)<br>Ard\u0131ndan damla say\u0131s\u0131n\u0131 \u00d7 2 hesaplay\u0131n<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\"><\/span>\u03b1-Asarone (Hint kam\u0131\u015f\u0131 ya\u011f\u0131, <em>Acorus calamus<\/em>) - do\u011frudan oligodendrosit koruyucu<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A\u015fa\u011f\u0131dakilere sahip birka\u00e7 aktif bile\u015fenden biri <strong>do\u011frudan remiyelinizasyon etkisi<\/strong> o <em><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37146420\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u03b1-Asaron<\/a><\/strong><\/em>. Astrositlerde PPAR-\u03b3'n\u0131n upreg\u00fclasyonu ve aktivasyonu ile hipoksi-iskemi sonras\u0131 olgun oligodendrositlerin kayb\u0131na ba\u011fl\u0131 dismiyelinizasyonu iyile\u015ftirir. Bu, glutamat ta\u015f\u0131y\u0131c\u0131 GLT-1'in ekspresyonunu art\u0131r\u0131r ve aksi takdirde OPC'lerde glutamat arac\u0131l\u0131 eksitotoksisiteye neden olacak, farkl\u0131la\u015fmalar\u0131n\u0131 engelleyecek ve h\u00fccre \u00f6l\u00fcm\u00fcne neden olacak a\u015f\u0131r\u0131 glutamat\u0131 h\u00fccre d\u0131\u015f\u0131 alandan uzakla\u015ft\u0131r\u0131r. <a href=\"https:\/\/www.klinikum.uni-heidelberg.de\/neurologische-klinik\/neurologie-und-poliklinik\/forschung\/neuroimmunology\/ag-molekulare-neuroimmunologie\/mog-enzephalomyelitis\" target=\"_blank\" rel=\"noreferrer noopener\">Heidelberg \u00dcniversite Hastanesi<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">N\u00f6rolojide PPARy - <a href=\"https:\/\/www.frontiersin.org\/journals\/neuroscience\/articles\/10.3389\/fnins.2022.1060515\/pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Frontiers Editoryal 2022<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dikkat:<\/strong> Kalamus ya\u011f\u0131, kayna\u011f\u0131na ba\u011fl\u0131 olarak, mutajenik olarak s\u0131n\u0131fland\u0131r\u0131lan \u03b2-asaron'u de\u011fi\u015fen miktarlarda i\u00e7erir. Sadece <strong>\u03b2-Asarone i\u00e7ermeyen nitelikler<\/strong> (Acorus calamus var. americanus).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mevcut duruma g\u00f6re (02.2026), pazar mevcudiyeti verilmemi\u015ftir.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\"><\/span>Sardunya ya\u011f\u0131 (<em>Pelargonium graveolens<\/em>) - N\u00f6roinflamasyon ve NO<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7922935\/\" rel=\"nofollow noopener\" target=\"_blank\">Sardunya ya\u011f\u0131<\/a> n\u00f6roinflamasyonun patofizyolojinin bir par\u00e7as\u0131 oldu\u011fu n\u00f6rodejeneratif hastal\u0131klarda faydal\u0131 olabilir.<br>Ana aktif bile\u015fen <em>Citronellol<\/em> daha y\u00fcksek konsantrasyonlarda NO \u00fcretimi \u00fczerinde m\u00fckemmel inhibit\u00f6r aktivite g\u00f6stermi\u015ftir, bu nedenle bile\u015fenler aras\u0131ndaki sinerjik etkile\u015fimler belirleyicidir.<br>Citronellol ayr\u0131ca MOGAD'daki mikroglial aktivasyonla do\u011frudan ilgili olan NF-\u03baB'yi de inhibe eder.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\"><\/span>\u00c7ay a\u011fac\u0131 ya\u011f\u0131 (<em>Melaleuca alternifolia<\/em>) - Mikroglia mod\u00fclasyonu<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10350368\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u00c7ay a\u011fac\u0131 ya\u011f\u0131<\/a> ve ana bile\u015fenleri AChE ve BChE'nin yan\u0131 s\u0131ra LOX'u da inhibe eder. Antioksidan \u00f6zellikler, n\u00f6roinflamasyon inhibisyonu ve AChE\/BChE inhibisyonu yoluyla oksidatif stresin optimizasyonu, genel bir strateji olarak n\u00f6ronal h\u00fccre \u00f6l\u00fcm\u00fcn\u00fcn \u00f6nlenmesine etkili bir \u015fekilde katk\u0131da bulunabilir.<br>Terpinen-4-ol (ana aktif bile\u015fen) ayr\u0131ca spesifik olarak mikroglia M1 polarizasyonunu inhibe eder.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wirkstoffubersicht_nach_MOGAD-Signalwegen\"><\/span>MOGAD sinyal yollar\u0131na g\u00f6re aktif maddelere genel bak\u0131\u015f<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aktif bile\u015fen<\/th><th>Ya\u011f kayna\u011f\u0131<\/th><th>MOGAD sinyal yolu<\/th><th>Kan\u0131tlar\u0131n g\u00fcc\u00fc<\/th><\/tr><\/thead><tbody><tr><td><strong>\u03b2-Karyofilen (BCP)<\/strong><\/td><td>Karabiber, Copaiba<\/td><td>CB2 \u2192 Nrf2\/HO-1, PPAR-\u03b3; Th17\u2193, IL-6\u2193<\/td><td>\u2605\u2605\u2605\u2605 (EAE modeli)<\/td><\/tr><tr><td><strong>AKBA<\/strong><\/td><td>Frankincense (<em>Boswellia serrata<\/em>)<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193, SPM\u2191, Nrf2\/HO-1\u2191<\/td><td>\u2605\u2605\u2605\u2605 (CNS \u00e7al\u0131\u015fmalar\u0131)<\/td><\/tr><tr><td><strong>\u0130nkensol asetat<\/strong><\/td><td>Frankincense (u\u00e7ucu k\u0131s\u0131m)<\/td><td>TRPV3, PPAR-\u03b3, IL-6\u2193, GFAP\u2193<\/td><td>\u2605\u2605\u2605 (hayvan modeli)<\/td><\/tr><tr><td><strong>\u03b1-Asaron<\/strong><\/td><td>Calamus (<em>Acorus calamus<\/em>)<\/td><td>PPAR-\u03b3 \u2192 GLT-1\u2191 \u2192 OPC korumas\u0131, do\u011frudan remiyelinizasyon<\/td><td>\u2605\u2605\u2605 (hipoksi modeli)<\/td><\/tr><tr><td><strong>Linalool<\/strong><\/td><td>Lavanta, melisa<\/td><td>NMDA mod\u00fclasyonu, SERT, n\u00f6roproteksiyon<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>1,8-Cineole<\/strong><\/td><td>Okalipt\u00fcs, biberiye<\/td><td>AChE inhibisyonu, antioksidan<\/td><td>\u2605\u2605\u2605 (beyinde kan\u0131tlanm\u0131\u015ft\u0131r)<\/td><\/tr><tr><td><strong>Citronellol<\/strong><\/td><td>Sardunya<\/td><td>NO\u2193, NF-\u03baB\u2193, sinerji etkileri<\/td><td>\u2605\u2605<\/td><\/tr><tr><td><strong>Terpinen-4-ol<\/strong><\/td><td>\u00c7ay a\u011fac\u0131<\/td><td>Mikroglia M1\u2193, LOX\u2193, AChE\u2193<\/td><td>\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen_und_weiterfuhrende_Literatur\"><\/span><strong>Kaynaklar ve daha fazla okuma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Banwell B ve di\u011ferleri - Lancet Neurol. 2023;22:268-282<\/strong> Tan\u0131 kriterleri MOGAD<br><strong>PubMed (\u00fccretsiz):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/<\/a> <br><strong>ScienceDirect (\u00d6zet \u00fccretsiz, tam metin \u00fccretli):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8<\/a><\/li>\n\n\n\n<li><strong>Mader S ve di\u011ferleri - PNAS 2023<\/strong> <em>(Not: Belgemizde \u201ePNAS 2024\" olarak ge\u00e7mektedir - do\u011fru yay\u0131n y\u0131l\u0131 Mart 2023't\u00fcr)<\/em> Kompleman ve FcR patomekanizmas\u0131, LMU M\u00fcnih<br><strong>PNAS tam metin (\u00fccretsiz):<\/strong> <a href=\"https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120<\/a> <br><strong>LMU bas\u0131n a\u00e7\u0131klamas\u0131 (a\u00e7\u0131klamal\u0131):<\/strong> <a href=\"https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html\" target=\"_blank\" rel=\"noopener\">https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html<\/a> <br><strong>EAN yorumu:<\/strong> <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad<\/a> <\/li>\n\n\n\n<li><strong>Kaneko K et al - Neurol Neuroimmunol Neuroinflamm. 2024;11(5):e200293<\/strong> BOS kompleman aktivasyonu<br>e200293 numaral\u0131 makale <strong>do\u011frudan bulunamaz<\/strong> - Bununla birlikte, ayn\u0131 say\u0131daki ilgili MOGAD inceleme makalesi (Moseley\/Zamvil taraf\u0131ndan e200275) mevcuttur:<br><strong>Neurology NXI (e200275, ayn\u0131 say\u0131):<\/strong> <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275<\/a> <br><strong>Kaneko 2024 MOGAD CSF i\u00e7in PubMed aramas\u0131:<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/<\/a> <em>(e200275'e y\u00f6nlendirir - e200293 i\u00e7in do\u011frudan PubMed aramas\u0131 \u00f6nerilir)<\/em><\/li>\n\n\n\n<li><strong>Cho EB ve di\u011ferleri - Front Immunol. 2024;15:1320094<\/strong> Tamamlay\u0131c\u0131 model MOGAD vs. NMOSD<br><strong>Frontiers (Tam metin \u00fccretsiz):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2024.1320094\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2024.1320094<\/a> <em>(DOI do\u011frudan eri\u015filebilir)<\/em><\/li>\n\n\n\n<li><strong>Frontiers Immunol. 2025 - EAE modelleri, MOGAD patogenezi<\/strong> <em>(Belgede genel olarak at\u0131fta bulunulmaktad\u0131r - bu, sinyal yollar\u0131\/pathomekanizmalar\u0131 hakk\u0131ndaki genel bak\u0131\u015f makalesine at\u0131fta bulunmaktad\u0131r)<\/em><br><strong>Frontiers Immunol. 2025 (Sun ve ark., PMID 40406135):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2025.1535571\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2025.1535571<\/a><\/li>\n\n\n\n<li><strong>PMC 2023 - Kapsaml\u0131 G\u00f6zden Ge\u00e7irme Patofizyoloji MOGAD<\/strong><br><strong>PMC Tam metin (\u00fccretsiz):<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/<\/a><\/li>\n\n\n\n<li><strong>PMC 2024 - G\u00fcncellenmi\u015f G\u00f6zden Ge\u00e7irme Klinik Spektrum, Patogenez, Tedavi<\/strong><br><strong>PubMed\/PMC (Trewin ve ark., Autoimmun Rev 2025):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/<\/a><br><strong>PMC tam metin:<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/<\/a> <em>(Monoklonal Antikor Tedavileri NMOSD\/MOGAD)<\/em><\/li>\n\n\n\n<li><strong>St\u00f6gbauer J ve di\u011ferleri - Otoimm\u00fcnite \u0130ncelemeleri 2025;103970<\/strong> Terap\u00f6tik Yakla\u015f\u0131mlar Yeti\u015fkinler MOGAD<br><strong>ScienceDirect (A\u00e7\u0131k Eri\u015fim, tam metin \u00fccretsiz):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/j.autrev.2025.103970\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/j.autrev.2025.103970<\/a> <br><strong>Almanca \u00f6zet:<\/strong> <a href=\"https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/<\/a> <\/li>\n\n\n\n<li><strong>Geli\u015fmekte Olan \u0130la\u00e7lar Hakk\u0131nda Uzman G\u00f6r\u00fc\u015f\u00fc 2025 - Klinik Deneme Ortam\u0131<\/strong><br><strong>Tandfonline (\u00d6zet \u00fccretsiz, tam metin \u00fccretli):<\/strong> <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189<\/a><br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1080\/14728214.2025.2565189<\/a><br><\/li>\n\n\n\n<li><strong>NEMOS \u00e7al\u0131\u015fma grubu<\/strong> <a href=\"https:\/\/www.nemos-net.de\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nemos-net.de<\/a><br><\/li>\n\n\n\n<li><strong>Hasta odakl\u0131 \u00e7al\u0131\u015fmaya genel bak\u0131\u015f (cosMOG\/METEOROID):<\/strong><br>MOG projesi - <a href=\"https:\/\/mogproject.org\/clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/mogproject.org\/clinical-trials\/<\/a><br>ClinicalTrials.gov - cosMOG - <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05063162\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05063162<\/a><\/li>\n<\/ul>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">T\u00fcm i\u00e7erikler titizlikle ara\u015ft\u0131r\u0131lm\u0131\u015f ve mevcut (02.2026) yay\u0131nlanm\u0131\u015f bilgi durumunu yans\u0131tmaktad\u0131r. Yaln\u0131zca bilgi ama\u00e7l\u0131d\u0131r ve profesyonel bir t\u0131bbi kons\u00fcltasyonun yerini almaz.<br>T\u00fcm dozaj \u00f6nerileri i\u00e7in ilgili doktor ile mutab\u0131k kal\u0131nmal\u0131d\u0131r. <br>Ba\u011flant\u0131l\u0131 \u00e7al\u0131\u015fmalar uygulay\u0131c\u0131ya daha fazla t\u0131bbi ve bilimsel bilgi sa\u011flar.<\/p>\n<\/blockquote>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Okuma s\u00fcresi<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">dakika<\/span><\/span>Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Was ist MOGAD? Jeder kennt elektrische Leitungen: Sie sind mit einer Isolierung versehen, die die einzelne Leiter im Kableb\u00fcndel von einander trennt, damit die Signale in ihnen einander nicht st\u00f6ren und unverf\u00e4lscht von A nach B gelangen.Das R\u00fcckenmark beinhaltet einen ganzen Strang vieler solcher Kabelb\u00fcndel. Sie leiten die Nervensignale vom&hellip;&nbsp;<a href=\"https:\/\/csiag.eu\/tr\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/\" rel=\"bookmark\">Daha fazlas\u0131n\u0131 oku \"<span class=\"screen-reader-text\">MOGAD - MOG antikoru ile ili\u015fkili hastal\u0131k<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[1078,354],"tags":[94,5721,5717,5720,5714,5713,5711,5715,5719,5716,77,90,5712,5718],"class_list":["post-12718","post","type-post","status-publish","format-standard","hentry","category-medizin","category-medizin-gesundheit","tag-antikoerper","tag-bcp","tag-glykoprotein","tag-igg","tag-mog","tag-mogad","tag-molekulare-signalwege","tag-myelin","tag-myelinscheide","tag-oligodendrozyten","tag-pathophysiologie","tag-rezeptoren","tag-therapiekonzepte","tag-transmebranprotein"],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/posts\/12718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/comments?post=12718"}],"version-history":[{"count":0,"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/posts\/12718\/revisions"}],"wp:attachment":[{"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/media?parent=12718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/categories?post=12718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.eu\/tr\/wp-json\/wp\/v2\/tags?post=12718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}